PCN285 - PRICE DIFFERENCES FOR ONCOLOGY DRUGS ACROSS THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT. (English)
- New search for: Cuesta, M.
- New search for: Prada, M.
- New search for: Berard, I.
- New search for: Vollmer, L.M.
- New search for: Guterres, S.
- New search for: Cuesta, M.
- New search for: Prada, M.
- New search for: Berard, I.
- New search for: Vollmer, L.M.
- New search for: Guterres, S.
In:
Value in health
;
21
, 3
;
S62
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:PCN285 - PRICE DIFFERENCES FOR ONCOLOGY DRUGS ACROSS THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT.
-
Contributors:Cuesta, M. ( author ) / Prada, M. ( author ) / Berard, I. ( author ) / Vollmer, L.M. ( author ) / Guterres, S. ( author )
-
Published in:Value in health ; 21, 3 ; S62
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam
-
Publication date:2018-01-01
-
Size:S62
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 610.28
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 610.28 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 21, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 249
-
Affordability of New Technologies: The Next FrontierTowse, Adrian / Mauskopf, Josephine A. et al. | 2018
- 252
-
Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and CuresDanzon, Patricia M. et al. | 2018
- 258
-
The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care ValuePearson, Steven D. et al. | 2018
- 266
-
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsLomas, James / Claxton, Karl / Martin, Stephen / Soares, Marta et al. | 2018
- 276
-
Paying for Cures: Perspectives on Solutions to the "Affordability Issue"Schaffer, Sarah Karlsberg / Messner, Donna / Mestre-Ferrandiz, Jorge / Tambor, Ellen / Towse, Adrian et al. | 2018
- 280
-
Affordability of Health Care: A Global CrisisWatkins, John B. et al. | 2018
- 283
-
Estimating the Learning Curve of a Novel Medical Device: Bipolar Sealer Use in Unilateral Total Knee ArthroplastiesKuznietsova, Victoria / Woodward, Robert S. et al. | 2018
- 295
-
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational StudyRapp, Thomas / Andrieu, Sandrine / Chartier, Florence / Deberdt, Walter / Reed, Catherine / Belger, Mark / Vellas, Bruno et al. | 2018
- 304
-
Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer PatientsZhong, Yue / Valderrama, Adriana / Yao, Jianying / Donga, Prina / Bilir, Pinar / Neumann, Peter J. et al. | 2018
- 310
-
Cost-Effectiveness of Antibiotic Prophylaxis Strategies for Transrectal Prostate Biopsy in an Era of Increasing Antimicrobial ResistanceLee, Kyueun / Drekonja, Dimitri M. / Enns, Eva A. et al. | 2018
- 318
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney DiseaseHabbous, Steven / Przech, Sebastian / Martin, Janet / Garg, Amit X. / Sarma, Sisira et al. | 2018
- 326
-
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?Malone, Daniel C. / Brown, Mary / Hurwitz, Jason T. / Peters, Loretta / Graff, Jennifer S. et al. | 2018
- 334
-
Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful UseHuo, Jinhai / Yang, Ming / Tina Shih, Ya-Chen et al. | 2018
- 341
-
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10, 000/QALY?Carroll, Christopher / Houten, Rachel / Boland, Angela / Kaltenthaler, Eva / Dickson, Rumona et al. | 2018
- 351
-
The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of HypertensionPeñaloza-Ramos, Maria Cristina / Jowett, Sue / Sutton, Andrew John / McManus, Richard J. / Barton, Pelham et al. | 2018
- 364
-
Associations of Smoking, Physical Inactivity, Heavy Drinking, and Obesity with Quality-Adjusted Life Expectancy among US Adults with DepressionJia, Haomiao / Zack, Matthew M. / Gottesman, Irving I. / Thompson, William W. et al. | 2018
- i
-
Table of Contents| 2018
- S2
-
CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALSRamos, M. / Foos, V. / Ustyugova, A.V. / Hau, N. / Gandhi, P. / Lamotte, M. et al. | 2018
- S3
-
CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER: MAPPING FROM EPIC TO PORPUSZamora, V. / À, Pont / Garin, O. / Pardo, Y. / Ferrer Fores, M. et al. | 2018
- S4
-
CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVECariou, C. / Tremblay, G. / Dolph, M. / Brandt, P.S. / Forsythe, A. et al. | 2018
- S5
-
CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS: HOW IGNORING THE MODEL'S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)Van Vlaenderen, I. / Moeremans, K. / Van Bellinghen, L. et al. | 2018
- S6
-
DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME: POPULATION-BASED DATA FROM THE NETHERLANDSHouben, E. / Heintjes, E. / Cremers, S. / Beekman, W. / Beest F, Penning-van / Stehouwer, C. / Herings, R. et al. | 2018
- S8
-
HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENTPisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
- S9
-
HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BAMacaulay, R. / Mohamoud, Z. / Schmidt, B. et al. | 2018
- S10
-
MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMABlommestein, H. / van Beurden-Tan, C. / de Groot, S. / Blijlevens, N. / Sonneveld, P. / Groot CA, Uyl-de / Zweegman, S. / Franken, M.G. et al. | 2018
- S11
-
ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER'STsong, W. / Jones, E. / Pike, J. / Bluff, D. et al. | 2018
- S12
-
PP4 - ONE SIZE DOES NOT FIT ALL: HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENTOstermann, J. / Derrick, C. / Yelverton, V. / Hobbie, A. / Weinhold, A. / Thielman, N. et al. | 2018
- S15
-
PCN5 - TREATMENTS OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN ROUTINE CLINICAL PRACTICE – A SYSTEMATIC REVIEWBhutani, M.K. / Rajora, P. / Soni, D. / Pan, J.J. et al. | 2018
- S16
-
PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITALMorales Perez, M. / Paladio-Hernandez, J.A. / Luna Mendoza, D. / Paredes-Garcia, P. / Munguia Juarez, L. / Sanchez Rodriguez, I. / Lopez-Luis, J. / Hernandez-Martinez, J. / Ramirez-Padilla, L. / Diaz-Rosales, S. et al. | 2018
- S17
-
PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMARoskell, N. / Gregory, J. / Wisniewski, T. / Thompson, G.J. / De la Cruz, C. et al. | 2018
- S18
-
PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAINSuarez, J. / Juarez-Garcia, A. / Shaw, J.W. / Contente, M. / Polanco, C. et al. | 2018
- S19
-
PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES: A COMPARISON IN NON-SMALL CELL LUNG CANCERvan Hooijdonk, I.E. / Lai, L. / van Engen, A. et al. | 2018
- S20
-
PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERChowdhury, S. / Oudard, S. / Hadaschik, B.A. / Uemura, H. / Joniau, S. / Pilon, D. / Ladouceur, M. / Behl, A. / Liu, J. / Dearden, L. et al. | 2018
- S21
-
PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)Adedokun, L. / Penaloza-Ramos, C. / Lee, J. et al. | 2018
- S22
-
PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORSLorenzi, M. / Amonkar, M. / Zhang, J. / Mehta, S. / Liaw, K. et al. | 2018
- S23
-
PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO: WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?Ben-Aharon, O. / Magnezi, R. / Leshno, M. / Goldstein, D.A. et al. | 2018
- S25
-
PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINAMacmullen, M. et al. | 2018
- S26
-
PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMKashiura, D. / Souza, P.V. / Garrido, S.D. / Nardi, E. / Alves, M. et al. | 2018
- S27
-
PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMABPoquet-Jornet, J.E. / Carrera Hueso, J. / Crespo, C. / Cuesta-Grueso, C. / Ramón Barrios, M.A. / Gasent-Blesa, J.M. / Fortuny-Organs, B. et al. | 2018
- S30
-
PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] DATAHupe, M.C. / Hammerer, P. / Ketz, M. / Kossack, N. / Colling, C. / Merseburger, A.S. et al. | 2018
- S31
-
PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALYAgirrezabal, I. / Gaikwad, I. / Cirillo, L. / Lothgren, M. et al. | 2018
- S32
-
PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMAShah, M.V. / McGovern, A. / Hepp, Z. et al. | 2018
- S34
-
PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREAPark, M. et al. | 2018
- S37
-
PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLANDTsoumani, E. / D'Oca, K. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
- S38
-
PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZILCarvalho, A.C. / Cao, Q. / van Asselt, A. / Sasse, A.D. / Postma, M.J. et al. | 2018
- S39
-
PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTSKourkoulas, N. / Athanasakis, K. / Kakouros, M. / Skroumpelos, A. / Kyriopoulos, J. et al. | 2018
- S40
-
PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCERZhou, Z. / Hu, X. et al. | 2018
- S41
-
PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLICDoležel, J. / Pour, M. / Skalický, D. / Fínek, J. et al. | 2018
- S42
-
PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCERJansen, J.P. / Incerti, D. / Shafrin, J. / Frederickson, A.M. / Lakdawalla, D.N. / Reckamp, K.L. et al. | 2018
- S43
-
PCN174 - NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECEBourhis, F. / Eriksson, J. / Ruffo, P. / D'Agostino, P. / Turini, M. et al. | 2018
- S44
-
PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIAKrysanova, V. / Krysanov, I. / Ermakova, V. et al. | 2018
- S46
-
PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSISNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
- S47
-
PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?Farinella, M. / Rubinstein, J. / Inumerable, R.V. / Gizaw, N. / Ho, Y. et al. | 2018
- S48
-
PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE: AN INTERNATIONAL PERSPECTIVEKamal, K.M. / Covvey, J.R. / Mehta, Z. / Zacker, C. et al. | 2018
- S49
-
PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORTSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S50
-
PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALYTucci, C. / Trimarchi, C. / Urbinati, D. / Demma, F. / Fico, M. / Fioravanti, L. et al. | 2018
- S51
-
PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSISSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S52
-
PCN227 - ACCESS TO ESSENTIAL ANTINEOPLASTICS AND IMMUNOSUPPRESSIVESKazaryan, I. / Sevikyan, A. / Amirkhanyan, A. / Melikyan, M. et al. | 2018
- S53
-
PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPELast, V. / Hickey, D.A. et al. | 2018
- S55
-
PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOWTolkushin, A. / Davydovskaya, M. / Ermolaeva, T. / Kokushkin, K. / Poliakova, K. et al. | 2018
- S56
-
PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5Rider, A. / Lewis, K. / Higson, O. et al. | 2018
- S58
-
PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.Solozabal, M. / De Prado, A. / Planellas, L. / Á, Baltasar-Sanchez / Carreño-Serra, A. / Callejo-Velasco, D. et al. | 2018
- S59
-
PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOMParikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Mann, H. / Wang, H. et al. | 2018
- S60
-
PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONSLiden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
- S61
-
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONSZou, D. / Desrosiers, N. / Wu, S. / Prawitz, T. / Tervonen, T. / Marsh, K. / Caro, J.J. et al. | 2018
- S62
-
PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIAOmelyanovskiy, V. / Avxentyeva, M. / Sura, M. / Savilova, A.G. / Khachatryan, G.R. et al. | 2018
- S63
-
PCN292 - CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASEMayer, F. / Hodek, J. / Walzer, S. et al. | 2018
- S64
-
PCN298 - MANAGEMENT OF ANTIEMETIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): PATIENTS', ONCOLOGISTS' AND NURSES' PERSPECTIVESDuracinsky, M. / Chassany, O. / Griffith, J. / Coblentz-Baumann, L. et al. | 2018
- S65
-
PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES: HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?Jonsson, B. / Chao, D. / Toumi, M. / Child, A. / Morris, J. / Hertel, N. et al. | 2018
- S66
-
PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS: A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.Filby, A. / Edwards, H.K. / Beggs, L. / O'Brien, S. et al. | 2018
- S67
-
PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGYLie, X. / Kempf, L. / van Engen, A. et al. | 2018
- S68
-
PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018): NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORTRebollo, P. / Hashim, M. / Gottschalk, F. / Ortega, T. / Heeg, B. / Wilke, T. et al. | 2018
- S69
-
PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5Caldeira, R. / Franceschetti, A. et al. | 2018
- S70
-
PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPYByrne, K. / Moon, R. / Chang, J. / Hubanova, P. / Doherty, J.P. / Cappelleri, J.C. et al. | 2018
- S72
-
PCN345 - HEALTH STATE UTILITIES IN METASTATIC NSCLC: A STUDY OF MULTIPLE IMMUNO-ONCOLOGY TRIALSHuang, M. / Chandwani, S. / Insinga, R. / Burke, T. / Pellissier, J. / Pickard, A.S. et al. | 2018
- S73
-
PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTATHudgens, S. / Floden, L. / Leoni, M. / Nikonova, E. / Quaglino, P. et al. | 2018
- S74
-
PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCERGregory, J. / Dyer, M. / Hoyle, C. / Mann, H. / Hatswell, A.J. et al. | 2018
- S75
-
PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATAMerinopoulou, E. / Cooper, O. / Hareendran, A. / Booth, A. / Faulkner, E.C. / Spinner, D.S. / Bruno, A. / Arjunji, R. et al. | 2018
- S76
-
PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEWSparano, F. / Aaronson, N. / Cottone, F. / Piciocchi, A. / La Sala, E. / Anota, A. / Deliu, N. / Kieffer, J.M. / Efficace, F. et al. | 2018
- S79
-
PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATESEkwueme, D.U. / Pollack, L.M. / Hung, M. / Khushalani, J.S. / Miller, J.W. / Chang, S. et al. | 2018
- S82
-
PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?Karppinen, M.L. / Ihalmo, P. / Hjortsberg, C. et al. | 2018
- S83
-
PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIESNevins, J.F. / Colasante, W. / Rahmati, D. et al. | 2018
- S84
-
PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SETCooper, S. / Bouvy, J. / Boysen, M. / Robertson, J. et al. | 2018
- S86
-
PCP34 - BIOSIMILARS: WHAT'S THE ISSUE?Mahi, L. / Barral, G. et al. | 2018
- S88
-
PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELSGal, P. / Kovacs, V. et al. | 2018
- S90
-
PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASESSzabo, S.M. / Johnston, K.M. et al. | 2018
- S91
-
PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIESRylands, A.J. / Boxell, E. / Bottomley, C.J. et al. | 2018
- S93
-
PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION: A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE USTsang, Y. / Drake, W. / Pruett, J. et al. | 2018
- S94
-
PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?Oh, J. / Tsitarava, M. / Loh, F.E. et al. | 2018
- S96
-
PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYFanelli, F. / Gazzi, L. / Heiman, F. / Peduto, I. / Pegoraro, V. et al. | 2018
- S97
-
PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIARomero, M. / Marino, C. / Cruz, A.M. / Rigueros, J. et al. | 2018
- S98
-
PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINAGiorgi, M.A. / Boissonnet, C.P. / Micone, P.V. / Gallo, M. / Stuart, P. / Giglio, N.D. et al. | 2018
- S99
-
PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTINGStafylas, P. / Karaiskou, M. / Zouka, M. et al. | 2018
- S100
-
PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS: A RETROSPECTIVE DATABASE STUDYXu, Y. / Liu, H. / Gao, Y. / Xuan, J. et al. | 2018
- S102
-
PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLANDDudek, D.Z. / Lamotte, M. / Sawicka, M. / Huczek, Z.J. / Depukat, R. / Rajtar-Salwa, R. / Krupiarz, M. / Duma, K. / Sidelnikov, E. et al. | 2018
- S103
-
PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTSOrlowski, A. / Slater, R. / Ashton, R. / Glover, R. et al. | 2018
- S104
-
PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISKGarcía-Goñi, M. / Fácila, L. / Cinza, S. / Pinto, X. / Cortes, X. / Prades, M. / Aceituno, S. et al. | 2018
- S105
-
PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLICKolek, M. / Weber, J. / Karbusicka, M. / Vothova, P. / Mazan, P. / Duba, J. et al. | 2018
- S106
-
PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOMLaskier, V. / Guy, H. / Fisher, M. / Neuman, W.R. / Bucior, I. / Deitelzweig, S.B. / Cohen, A. et al. | 2018
- S107
-
PCV91 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL KNEE REPLACEMENT SURGERY: A COST-UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONDawoud, D. / Wonderling, D. / Lewis, S. / Glen, J. / Griffin, X. / Reed, M. / Rossiter, N. / Stansby, G. / Hunt, B.J. / Chahal, J.K. et al. | 2018
- S108
-
PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)Annemans, L. / Azuri, J. / Al-Rasadi, K. / Al-Zakwani, I. / Daclin, V. / Mercier, F. / Danchin, N. et al. | 2018
- S109
-
PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES: DESPEGA STUDYAceituno, S. / Millan, J. / Rodriguez, P. / Rodríguez de Miguel, M. / Melogno Klinkas, M. / Orera - Peña, M.L. et al. | 2018
- S110
-
PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION: A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABANSchinle, P. / Keogh-Bootland, S. / du Feu, J. / Durno, K. / How, W.J. / Hill, N. / Gordon, J. / Sugrue, D. / Beresford, L. / Lister, S. et al. | 2018
- S111
-
PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAELWeitzman, D. / Bourvine, L. / Tirosh, M. / Shalev, V. / Chodick, G. et al. | 2018
- S112
-
PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINSAndretta, M. / Degli Esposti, L. et al. | 2018
- S113
-
PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTSKo, A. / Choi, S. / Chang, J. / Park, S.M. et al. | 2018
- S114
-
PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING: HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTIONJacobs, M.S. / van Hulst, M. / Campmans, Z. / Tieleman, R.G. et al. | 2018
- S115
-
PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATIONNatani, H. / Gogna, S. / Jindal, R. / Laires, P.A. / Cristino, J. et al. | 2018
- S116
-
PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)Afonso-Silva, M. / Laires, P.A. / Gonçalves, C. / Cary, M. / Guerreiro, J.P. / Romão, M. / Teixeira Rodrigues, A. et al. | 2018
- S117
-
PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONGLee, V.W. / So, S.C. / Yeo, J. / Yan, B.P. et al. | 2018
- S119
-
PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Sha'aban, A. / Mohamed Noor, D.A. et al. | 2018
- S120
-
PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONSBalijepalli, C. / Ayers, D. / Kandaswamy, P. / Ustyugova, A.V. / Pfarr, E. / Lund, S.S. / Druyts, E. et al. | 2018
- S122
-
PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE: A CLAIMS DATA ANALYSISGabler, M. / Picker, N. / Mueller, S. / Wilke, T. / Geier, S. / Försch, J. / Aberle, J. / Martin, S. / Riedl, M. et al. | 2018
- S123
-
PDB32 - SEX- AND SITE-SPECIFIC DIFFERENCES IN COLORECTAL CANCER RISK AMONG PEOPLE WITH TYPE 2 DIABETESOverbeek, J.A. / Kuiper, J.G. / van der Heijden, A.A. / Labots, M. / Haug, U. / Herings, R.M. / Nijpels, G. et al. | 2018
- S124
-
PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES &ENHANCEMENT PATIENT'S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASEAbotaleb, A. / Amin, M. et al. | 2018
- S125
-
PDB46 - CLINICAL AND ECONOMIC BURDEN OF TYPE 1 DIABETES IN REAL-LIFE SETTING IN SPAINSicras-Mainar, A. / Navarro-Artieda, R. et al. | 2018
- S126
-
PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
- S127
-
PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLICLoncak, V. / Bartak, M. / Rogalewicz, V. et al. | 2018
- S128
-
PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETESLanger, J. / Wolden, M.L. / Shimoda, S. / Sato, M. / Araki, E. et al. | 2018
- S129
-
PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRANDavari, M. / Khorasani, E. / Savari Shojaei, R. / Akbari, Sari A / Saiyarsarai, P. et al. | 2018
- S130
-
PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLICRussel-Szymczyk, M. / Parekh, W. / Rychna, K. / Pöhlmann, J. / Hunt, B. et al. | 2018
- S131
-
PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIABogdanovic, M. / Fournier, M. / Vitezic, D. et al. | 2018
- S132
-
PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM: HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
- S133
-
PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMENFitria, N. / Utama, B. / Pradipta, I. / Schmidt, A. / van Asselt, A. / Postma, M.J. et al. | 2018
- S134
-
PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES: IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENTAscenção, R. / Fiorentino, F. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
- S135
-
PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK: A RETROSPECTIVE COHORT STUDYSpanopoulos, D. / Poole, C. / Barrett, B. / Busse, M. / Roman, T. / Khunti, K. et al. | 2018
- S137
-
PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING: A RETROSPECTIVE STUDYDegli Esposti, L. / Perrone, V. / Saragoni, S. / Blini, V. / D'Avella, R. / Gasperini, G. / Lena, F. / Fanelli, F. / Gazzi, L. / Giorgino, F. et al. | 2018
- S138
-
PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALYMatza, L.S. / Osumili, B. / Stewart, K.D. / Perez, M. / Jordan, J. / Biricolti, G. / Romoli, E. / Losi, S. / Del Santo, S. / Spaepen, E. et al. | 2018
- S139
-
PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURESMcNamara, M. / Westhead, H. / Gross, H. / Turner-Bowker, D.M. / Yaworsky, A. / Pleil, A. / Loftus, J.V. et al. | 2018
- S140
-
PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLANDRuotsalainen, J. / Balcerzak, M. et al. | 2018
- S142
-
PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATIONOkumura, H. / Tang, W. / Iwasaki, K. / Shoji, S. / Odaka, T. / Nakajima, A. et al. | 2018
- S143
-
PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACYMargusino-Framiñán, L. / Cid-Silva, P. / Mena-de-Cea, A. / Vazquez-Rodriguez, P. / Rodriguez-Osorio, I. / Lopez-Calvo, S. / Pernas-Souto, B. / Martin-Herranz, I. / Castro-Iglesias, A. et al. | 2018
- S147
-
PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS: THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTSSchmetz, A. / Petrakis, I. / Khalid, J.M. / Minda, K. / Agboton, C. / Rawson, K. / Baumgart, D.C. et al. | 2018
- S148
-
PGI44 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT POSITIVE EXPERIENCE AFTER PARTICIPATING IN AN ONLINE QUANTITATIVE PREFERENCE SURVEYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
- S149
-
PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS: RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)Balp, M. / Krieger, N. / Przybysz, R. / Way, N. / Cai, J. / Zappe, D. / Mckenna, S.J. / Wall, G. / Janssens, N. / Tapper, E. et al. | 2018
- S151
-
PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE: VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIMEHöglinger, M. / Knöfler, F. / Scholz, S. / Schaumann-von Stosch, R. / Eichler, K. et al. | 2018
- S152
-
PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESSIpolyi, D. / Molnár, A. / Oláh, A. / Karácsony, I. / Pakai, A. / Brantmüller, É. / Boncz, I. / Breitenbach, Z. et al. | 2018
- S153
-
PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARYPónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
- S154
-
PHP25 - MENTAL HEALTH COMORBIDITIES AND ELEVATED RISK OF OPIOID USE IN ELDERLY BREAST CANCER SURVIVORS USING ADJUVANT ENDOCRINE TREATMENTSDesai, R.A. / Camacho, F. / Tan, X. / LeBaron, V. / Blackhall, L. / Balkrishnan, R. et al. | 2018
- S155
-
PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANYJones, C. / Cocklin, S.L. et al. | 2018
- S156
-
PHP36 - EU5 AND PHARMACEUTICAL RESPONSES TO THE SPREAD OF CARBAPENEM-RESISTANT BACTERIA: A POLICY AND PIPELINE REVIEWCollings, H. / Palmer, T. / Tavella, F. et al. | 2018
- S157
-
PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT'S THE DIFFERENCE?Mueller, E. / Neeser, K. / Oelze, I. et al. | 2018
- S158
-
PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS: APPLY LIBERALLY OR USE SPARINGLY?Lockwood, C. / Rodrigues, T. / Ando, G. et al. | 2018
- S159
-
PHP56 - EARLY ACCESS PROGRAMS: AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALYD'Ausilio, A. / Seyed Khoei, N. / Lanati, E.P. et al. | 2018
- S160
-
PHP62 - HOME BREWED AUTOLOGOUS THERAPIES: CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL & GENE THERAPY MANUFACTURERS?Khurana, S. / Kumar, A. / Sotou, D.S. et al. | 2018
- S161
-
PHP67 - CURRENT INITIATIVES & FUTURE OF E-HEALTH FUNDING PATHSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
- S162
-
PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING: SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARISAdé, A. / Degrassat-Théas, A. / Bocquet, F. / Parent de Curzon, O. / Paubel, P. et al. | 2018
- S163
-
PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPMMacaulay, R. / Fernandez Dacosta, R. et al. | 2018
- S165
-
PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECECherneva, D. / Benisheva, T. et al. | 2018
- S166
-
PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIAMittal, P. / Lai, K.Y. / Verma, R.K. / Hasan, S.S. et al. | 2018
- S167
-
PHP105 - A POPULATION-BASED DATA ANALYSIS OF DRUG PRESCRIPTION AND PATTERNS OF USE OF ANTIBIOTIC IN SOUTHERN ITALY POPULATIONMoreno Juste, A. / Guarino, I. / Russo, V. / Menditto, E. et al. | 2018
- S168
-
PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION: ANALYTICS FOR EUROPEVandewalle, B. / Félix, J. / Ferreira, C. et al. | 2018
- S170
-
PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS: A SURVIVAL MODEL ANALYSISCima, J. / Almeida, A.S. et al. | 2018
- S171
-
PHP128 - 3F - FORMULA FOR FUNDING: RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEMLourenço, A. / Ventura, C. / Andrade, S. / Sousa, J. / Valadas, F. et al. | 2018
- S173
-
PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE: IMPACT ON HTA OUTCOMES AND PRICEDehnen, J. / Petry, D. / Kruse, F. / Bercher, J. et al. | 2018
- S174
-
PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGALCorreia, S. / Yantsides, C. / Amorim, A.P. / Monteiro, J.L. / Costa, L. / Gonçalves, A.M. / Azevedo, A. / Paiva, J.A. et al. | 2018
- S175
-
PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY: A LITERATURE REVIEWFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
- S176
-
PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMESLewis, M. / Tavella, F. / Okhuoya, P. et al. | 2018
- S178
-
PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD: INITIAL ESTIMATES IN REPUBLIC OF BELARUSKozhanova, I. / Sachek, M. et al. | 2018
- S180
-
PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVERLe Pen, C. / Sclison, S. / Ravonimbola, H. / Paolantonacci, J. / Baseilhac, E. / Savart, P. / Dorizon, D. / Vigneron, A. et al. | 2018
- S181
-
PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATIONRavindra, S. / Boehler, Y. et al. | 2018
- S182
-
PHP193 - THE USE OF MEDTECH INNOVATION BRIEFINGS (MIBS) TO ENCOURAGE IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES: A REVIEW OF PUBLISHED BRIEFINGS FROM 2014-2018Glen, F. / Pulfer, A. et al. | 2018
- S184
-
PHP206 - TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?Khogeer, B. / Anjarwalla, N. / Doolub, N. / Grosvenor, A. et al. | 2018
- S185
-
PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE: ISSUES AND WAYS FOR IMPROVEMENTDobrova, V. / Zupanets, I. / Shilkina, O. / Lishchyshyna, O. et al. | 2018
- S186
-
PHP217 - TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5López, N. / Prada, M. / Berard, I. / Schleich, W. / Melson, C. et al. | 2018
- S187
-
PHP222 - IDENTIFYING THE KEY DRIVERS AFFECTING THE REIMBURSEMENT OF THERAPEUTIC VACCINES IN EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Narjal, M. / Yadav, V. / Shah, C.S. et al. | 2018
- S189
-
PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS: NOT ALWAYS A NICE OUTCOMEGriffiths, E.A. et al. | 2018
- S190
-
PHP238 - CARER DISUTILITY: IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?Ferizovic, N. / Marshall, J.D. et al. | 2018
- S191
-
PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTSVandewalle, C. / Charoy, M. / Heurtebis, J. / Desplanches, L. / Gauthier, M. / de Sauvebeuf, C. et al. | 2018
- S192
-
PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN'S HEALTH QUESTIONNAIRE AGAINST THE EQ-5D-5L AND SF-6DKaambwa, B. / Ratcliffe, J. et al. | 2018
- S193
-
PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOLXia, A. / Schaefer, C. / Szende, A. / Jahn, E. / Dunlop, W. et al. | 2018
- S194
-
PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELINGMaskineh, C. / Becker, R.V. / Kosremelli Asmar, M. / Bekhazi, H. / Sleilaty, G. et al. | 2018
- S195
-
PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICEFerenczy, M. / Dudás, M. / Pakai, A. / Karácsony, I. / Boncz, I. / Rozmann, N. / Komlósi, K. / Oláh, A. et al. | 2018
- S197
-
PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA: AN EMPIRICAL APPROACHPanni, T. / Thiele, A. / Carls, A. / Wallstab, A. / Eberle, K. / Schleibner, S. et al. | 2018
- S198
-
PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKSOyeye, O. / Johnson, K.I. et al. | 2018
- S199
-
PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTSWillemsen, A. / Estevão, S. / Dupree, R. et al. | 2018
- S200
-
PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Wordsworth, J. / Cork, D. / Curry, A. / Ralston, S. et al. | 2018
- S202
-
PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPEHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S203
-
PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCECabout, E. / Launois, R. et al. | 2018
- S204
-
PHP319 - MANDATORY JOINT CLINICAL ASSESSMENT – WHAT IS THE ADDITIONAL INSIGHT FROM EU-NETHTA VS. EMA?Ecker, T. et al. | 2018
- S207
-
PHP337 - OFF-LABEL PRESCRIPTION OF DRUGS COMPARED TO PRESCRIPTION AFTER LABEL EXTENSION IN CHILDREN FOR GERMANYGohlke, A. / Kostev, K. / Kuschel, A. et al. | 2018
- S208
-
PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVEHenriques, J. / Amorim, A. et al. | 2018
- S209
-
PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY: A BUDGET IMPACT ANALYSISHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S210
-
PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGSRadu, P. / Stoica, I. / Udroiu, P. et al. | 2018
- S211
-
PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5Izmirlieva, M.A. / Reinaud, F. / Ando, G. et al. | 2018
- S212
-
PHP365 - TRENDS AND CHARACTERISTICS OF MANAGED ACCESS AGREEMENTS APPROVED BY NICEMarsh, S.E. et al. | 2018
- S214
-
PIH7 - LONG-ACTING RECOMBINANT FSH (CORIFOLLITROPIN ALFA) VERSUS RECOMBINANT FSH AS ASSISTED REPRODUCTION TECHNIQUES IN THE MANAGEMENT OF INFERTILITY: A SYSTEMATIC REVIEW AND META-ANALYSISTaheri, S. / Varmaghani, M. / Heidari, E. / Yousefi, N. / Peiravian, F. et al. | 2018
- S216
-
PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALYKriz, A. / Migliore, A. / Wright, A. / Piaggio, T. et al. | 2018
- S223
-
PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOMWeidlich, D. / Hicks, M.D. / Floros, L. / Patel, J. / Charbonneau, C. / Sung, A.H. et al. | 2018
- S224
-
PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCEFievez, S. / Tin Tin Htar, M. / Goguillot, M. / Bénard, S. / Huang, L. et al. | 2018
- S225
-
PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTINGFerreira, J. / Pereira, R. / Schelfhout, J. / Jiang, Y. et al. | 2018
-
PHP370 - AMBULATORY CARE TRENDS IN THE EMERGENCY DEPARTMENTBuchenberger, J.D. / Noone, J.M. / Abrigo, M.B. et al. | 2018
-
PIH18 - DIRECT COST OF UNINTENDED PREGNANCIES IN JAPAN: ESTIMATING POTENTIAL IMPACTS WITH INCREASED USE OF MODERN CONTRACEPTIVESAkiyama, S. / Murata, T. / Kidoguchi, Y. / Osuga, Y. et al. | 2018
-
PHP361 - PIM AND EAMS: THE IMPACT OF PROMISING MEDICINE DESIGNATION IN ACHIEVING PATIENT ACCESSNikolettos, J. / Gapper, A. et al. | 2018
-
PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMYLeaper, D.J. / Holy, C.E. / Chen, B.P. / Ghosh, E. / Edmiston, C.E. et al. | 2018
-
PHP192 - HTA EDUCATIONAL NEEDS IN CENTRAL-EASTERN-SOUTH EUROPEAN (CESE) COUNTIRES – RESULTS OF JOC HTA PROJECTHermanowski, T.R. / Zawada, A. et al. | 2018
-
PHP187 - BEST PRACTICES FOR REAL WORLD EVIDENCE (RWE) COLLECTION FOR CELL AND GENE THERAPIESKhurana, S. / Kumar, A. et al. | 2018
-
PHP174 - ARE FIXED THERAPEUTIC-LEVEL SPENDING CAPS ADVISABLE FOR THE GREEK OUTPATIENT MARKET? METHODOLOGICAL ISSUES AND HEALTH POLICY PROPOSALSCharonis, A. / Papageorgiou, M. / Kontoudis, I. / Karokis, A. et al. | 2018
-
PHP162 - LICENCED ORPHAN MEDICINES EXPENDITURE IN TURKEYNacar, S. / Atikeler, K. / Beyan, A. / Safak Yilmaz, E. / Bayar, B. / Vural, I.M. et al. | 2018
-
PHP166 - TOOLS OF THE TRADE: PAYER APPROACHES TO HIGH PATIENT VOLUME, PREMIUM PRICED THERAPIESVassoler, H. / Spoors, J. et al. | 2018
-
PHP104 - PRESCRIPTION DRUG USE AND INAPPROPRIATE PRESCRIBING AMONG PREGNANT WOMEN IN SOUTH KOREAKim, A. / Lee, H. / Kang, H. et al. | 2018
-
PHP107 - THE STRUCTURE OF CONSUMPTION OF ANTIMICROBIAL DRUG FOR SYSTEMIC USE IN MULTIDISCIPLINARY HOSPITALS IN ST.PETERSBURG IN 2014-2015Gomon, J. / Kolbin, A. / Kurylev, A. et al. | 2018
-
PHP42 - EARLY ACCESS PROGRAMS: A COMPARISON BETWEEN FRANCE, GERMANY AND THE UNITED KINGDOMBen Younes, K. / Foix Colonier, A. / Amzal, B. / Angehrn, Z. / Karcher, H. et al. | 2018
-
PHP24 - ANALYSIS OF SPANISH THERAPEUTIC POSITIONING REPORTS PUBLISHED UNTIL 2017López, N. / Pomares, E. / Cuesta, M. et al. | 2018
-
PHP9 - PATIENT INVOLVEMENT IN THE DRUG LIFE CYCLE ACCORDING TO STAKEHOLDERS: EXPLORING THE GAP BETWEEN THEORY AND PRACTICEJanssens, R. / van Overbeeke, E. / Verswijvel, L. / Meeusen, L. / Coenegrachts, C. / Pauwels, K. / Dooms, M. / Stevens, H. / Simoens, S. / Huys, I. et al. | 2018
-
PHP5 - DEVELOPMENT OF THE PATIENT ORGANISATION SUBMISSION PROCESS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE), IRELANDHanevy, A. / Gorry, C. / Tilson, L. / O'Leary, A. / Barry, M. et al. | 2018
-
PGI47 - OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES IN IRRITABLE BOWEL SYNDROME PATIENTS: A RETROSPECTIVE ANALYSIS OF A LARGE U.S. ELECTRONIC HEALTH RECORD DATABASEPeyerl, F.W. / Shenoy, A. / Hayashida, D.K. / D'Souza, F.T. et al. | 2018
-
PGI42 - NON-PERSISTENCE WITH IMMUNOSUPPRESANT, ANTI-TUMOR NECROSIS FACTOR, AND ANTI-INTEGRIN AGENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANYWilke, T. / Groth, A. / Long, G.H. / Tatro, A.R. / Sun, D. et al. | 2018
-
PGI37 - UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C MANAGED BY THE HOSPITAL PHARMACY: CONTRIBUTIONS TO PUBLIC HEALTH AND PUBLIC EXPENDITUREFigueira, A. / Gomes, I. / Sequeira, C. / Silva, S. / Machado, F. / Figueiredo, J. / Rabadão, E. / Dinis, P. / Andreozzi, V. / Vandewalle, B. et al. | 2018
-
PDB122 - THE EFFECTS OF TYPE 2 DIABETES ON HEALTH-RELATED QUALITY OF LIFE IN THE FINNISH POPULATION AS MEASURED WITH EQ-5D-5LJalkanen, K. / Aarnio, E.J. / Lavikainen, P.T. / Jauhonen, H.M. / Enlund, H. / Martikainen, J.A. et al. | 2018
-
PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETESRamos, M. / Foos, V. / Ferrufino, C. / Yu-Isenberg, K. / Lamotte, M. et al. | 2018
-
PGI31 - PATTERNS OF ANTI-TNF ADOPTION AND DIFFUSION: REAL WORLD EVIDENCE FROM A 12-YEAR COHORT OF CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN TERTIARY REFERAL MEDICAL CENTERS IN ISRAELSergienko, R. / Schwartz, D. / Odes, S. / Greenberg, D. et al. | 2018
-
PDB126 - FACTORS INFLUENCING FOOD CHOICES OF PEOPLE WITH TYPE 2 DIABETES: A Q METHODOLOGY STUDYHubens, K. / van Exel, N.J. et al. | 2018
-
PHP341 - ARE THERE ENOUGH REGULATIONS TO COMBAT THE POOR QUALITY POVIDONE-IODINE IN EGYPTHamdy El-sisi, G. / Emad, S. / Hamed, A. et al. | 2018
-
PHP330 - REAL-WORLD DATA COLLECTION ON MEDICAL DEVICES IN THE ERA OF VALUE-BASED HEALTHCARE: A LITERATURE REVIEWRizzo, E. / Buseghin, G. / Greco, T. / Murphy, J. / Pinciroli, M. / Mordenti, G. et al. | 2018
-
PHP329 - THE REGISTRY EVALUATION AND QUALITY STANDARDS TOOL (REQUEST) FOR HEALTH TECHNOLOGY ASSESSMENT FROM AN OUTCOMES ASSESSMENT PERSPECTIVEGimenez, E. / Espallargues, M. / Rodrigues, J. / Varela, L. / Patrick, H. / Jae, L. / Maja, V. / Guzina, I. et al. | 2018
-
PHP321 - THE HTA APPROACH OF NOVEL TREATMENTS IN THE CENTRAL EASTERN EUROPEAN COUNTRY FOR FIVE YEARS PERIOD (2013-2017): THE CASE OF BULGARIABenisheva Dimitrova, T. / Stoimenova, A. / Sidzhimova, D. / Atanasova, R. et al. | 2018
-
PHP306 - CAN GRADEPRO SUPPORT AND IMPROVE CHOICE OF OUTCOMES IN HEALTH TECHNOLOGY ASSESSMENT? REPORT ON A PILOT USE WITHIN THE EUNETHTA ASSESSMENT OF FEMTOSECOND LASER ASSISTED CATARACT SURGERY (FLACS)Ballini, L. / Bonvicini, L. / Bottazzi, P. / Eisenmann, A. / Formoso, G. / Giorgi Rossi, P. / Rosian-Schikuta, I. / Venturelli, F. / Vicentini, M. / De Laet, C. et al. | 2018
-
PHP297 - CHANGES IN ULTRA-ORPHAN DRUG ASSESSMENTS IN POLANDVaithyanathan, G. / Dekkers, R. / van Engen, A. et al. | 2018
-
PHP293 - ORPHAN DRUGS IN GERMANY - LESSONS LEARNED FROM AMNOG, BEST AND WORST PRACTICES AND STRATEGIC IMPLICATIONSKirchmann, T. / Ewald, A. / Schönermark, M. et al. | 2018
-
PHP275 - ORPHAN MEDICINAL PRODUCTS GIVEN AN INITIAL NEGATIVE RECOMMENDATION BY NICE'S STA PROCESS BUT APPROVED FOLLOWING RE-EVALUATION IN ENGLANDForsyth, C. et al. | 2018
-
PHP285 - EXPERTS IN HEALTH TECHNOLOGY ASSESSMENT ARE CONCERNED ABOUT THE TRANSLATION FROM EVIDENCE TO DECISION-MAKINGShih, T. / Toor, K. / Yoon, L. / Barron, R. / Cope, S. / Huber, C. / Arellano, J. / Jansen, J.P. et al. | 2018
-
PHP287 - GERMAN EARLY BENEFIT ASSESSMENTS OF ORPHAN DRUGS UNDER FULL DOSSIER CONDITIONSKirchmann, T. / Schönermark, M. / Ewald, A. et al. | 2018
-
PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS: COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?Hnoosh, A. / Courmier, D.F. et al. | 2018
-
PHP244 - BRIDGING THE GAP: ENSURING FAIR ASSESSMENT OF ORPHAN TREATMENTS BY HEALTH TECHNOLOGY ASSESSMENTS IN ENGLANDFerizovic, N. / Hughes, T. et al. | 2018
-
PHP242 - AN ANALYSIS OF THE TIMELINES THROUGHOUT THE REIMBURSEMENT PATHWAY FOR DRUGS IN IRELANDConnolly, E. / Lamrock, F. / O'Donnell, H. / Walsh, C. / Tilson, L. / Barry, M. et al. | 2018
-
PDB93 - IMPACT OF CARDIOVASCULAR DISEASE ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES IN A REAL WORLD SETTINGWeng, W. / Tian, Y. / Kong, S.X. / Ganguly, R. / Hersloev, M. / Brett, J. / Hobbs, T. et al. | 2018
-
PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIABogdanovic, M. / Mihajlović, J. / Fournier, M. et al. | 2018
-
PDB60 - COST-CONSEQUENCE ANALYSIS FOR RECOMBINANT HUMAN GROWTH HORMONE TREATMENT ADMINISTERED VIA DIFFERENT DEVICES IN CHILDREN WITH GROWTH HORMONE DEFICIENCY IN ITALYCentonze, C. / Foo, J. / Vlachaki, I. / Novelli, P. et al. | 2018
-
PDB59 - COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC (IDEG) U100 FROM CURRENTLY AVAILABLE BASAL INSULINS IN BELGIUM BASED ON EVIDENCE FROM REAL-WORLD CLINICAL PRACTICEOlivieri, A. / Vandebrouck, T. / Hvid, C. et al. | 2018
-
PDB48 - ANNUAL COST OF ILLNESS OF ISCHEMIC STROKE IN TYPE 2 DIABETIC PATIENTS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
-
PDB29 - TYPE 2 DIABETES: DISCONTINUATION OF ANTIDIABETIC DRUG DISPENSING 8 YEARS AFTER STARTING TREATMENT: A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)Aguade, A. / Gastaldi-Menager, C. / Karsenty, D. / Semenzato, L. / Fontaine, P. / Fagot-Campagna, A. et al. | 2018
-
PDB37 - BUDGET IMPACT ANALYSIS OF THE ADULT TYPE 1 DIABETES MELLITUS NATIONAL CLINICAL GUIDELINE IN IRELANDCarty, P. / O'Neill, M. / Harrington, P. / Smith, S. / Ryan, M. et al. | 2018
-
PDB2 - COMPARISON OF ATORVASTATIN AND SIMVASTATIN EFFECT ON GLYCATED HEMOGLOBIN CONTROL AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV112 - PATTERN OF USE OF ANTIHYPERTENSIVE DRUGS IN TWO EUROPEAN COUNTRIES: COMPARISON OF THE INDEX THERAPIES AND PERSISTENCEMalo, S. / Aguilar, I. / Russo, V. / Feja, C. / Orlando, V. / Rabanaque, M. / Lallana, M. / Menditto, E. et al. | 2018
-
PCV116 - DISCONTINUATION AND HEALTH CARE RESOURCE UTILISATION IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH APIXABAN OR WARFARIN IN ENGLANDGraham, S. / Raluy-Callado, M. / Donaldson, R. / Colby, C. / Carroll, R. / Nordstrom, B. / Stynes, G. / Hill, N. / Ramagopalan, S. / Alikhan, R. et al. | 2018
-
PCV107 - MULTI-CRITERIA DECISION ANALYSIS (MCDA) - DISCUSSION ABOUT THE INCORPORATION OF RIOCIGUAT IN THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) UNDER THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)Carvalho, D.N. / Etto, H.Y. / Kim, H.S. / Nakada, C. / ÉJ, Peixoto de Miranda / Tannus, G. et al. | 2018
-
PCV99 - ANALYSIS OF MEAN AGE OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION IN HUNGARY, 2010-2017Németh, N. / Endrei, D. / Elmer, D. / Horváth, L. / Csákvári, T. / Pónusz, R. / Boncz, I. et al. | 2018
-
PCV81 - COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN FOR HIGH-RISK PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE IN CHINALin, Z. / Zhang, L. / Yang, X. / Liu, L. / Xuan, J. et al. | 2018
-
PCN261 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH COLORECTAL CANCER IN SPAINPlanellas, L. / Solozabal, M. / Barrull, C. / De Prado, A. / Canal-Díaz, N. / Gómez-Navarro, V. et al. | 2018
-
PCN275 - HOW DO HTA DECISIONS FOR NEW DISEASE CONDITIONS IMPACT TIME TO PRICE CHANGES?Liden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
-
PCN218 - PERSONALIZED THERAPY DEVELOPMENT IN NSCLC DEMONSTRATES INTERSECTION BETWEEN INNOVATION AND POSITIVE COVERAGE DECISIONSEslami, N. / Lehmann, H. / Garfield, S. / Erickson, G. et al. | 2018
-
PCN226 - BIOSIMILARS AND THE REGULATION OF ONCOLOGICAL PREPARATIONS IN GERMANYWalendzik, A. / Wasem, J. / Altin, S. / Bauer, C. / May, U. et al. | 2018
-
PCN155 - COST-EFFECTIVENESS OF CPX-351 VERSUS 3+7 AMONG PATIENTS <60 YEARS OF AGE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED KINGDOM (UK)Kansal, A. / Reifsnider, O. / Khankhel, Z. / Todorova, L. / Dorman, E. / Coughlan, A. / Hoog, M. / Villa, K. et al. | 2018
-
PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEYÖksüz, E. / Malhan, S. / Yanik, L. / Koc, E. / Erdogan-Ciftci, E. / Guler, B. / Orfanos, P. et al. | 2018
-
PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN'S LYMPHOMA: A COST-EFFECTIVENESS ANALYSISRaymakers, A. / Costa, S. / Peacock, S.J. / Regier, D. et al. | 2018
-
PCN141 - COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECEVellopoulou, K. / Tzanetakos, C. / Theodoropoulou, T. / Akratos, A. / Maniadakis, N. et al. | 2018
-
PCN131 - ASSESSING THE REAL-WORLD COST OF CARE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN THE UNITED STATESSkinner, K.E. / Dufour, R. / Haiderali, A. / Huang, M. / Schwartzberg, L.S. et al. | 2018
-
PCN134 - USE OF LIQUID BIOPSY IN METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: A COST CONSEQUENCE ANALYSIS.Gancitano, G. / Almeida Gerolami, G. / Ravasio, R. / Cortinovis, L.D. / Dionisi, M. et al. | 2018
-
PCN120 - EPIDEMIOLOGY AND COSTS OF NON-SMALL CELL LUNG CANCER (NSCLC) IN AUSTRIAWalter, E. / Hausberger, S. / Lazic-Peric, A. et al. | 2018
-
PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN FRANCELafuma, A. / Cotté, F. / Le Tourneau, C. / Emery, C. / Gaudin, A. / Torreton, E. / Gourmelen, J. / Bonastre, J. et al. | 2018
-
PCN101 - COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH MAINTENANCE THERAPY IN MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEWCherepanov, D. / Kayaniyil, S. / Huang, H. / Romanus, D. / Labotka, R. / Zagadailov, E. / Khan, Z. et al. | 2018
-
PCN78 - EVALUATING THE ECONOMIC CONSEQUENCES OF NOVEL AGENTS FOR TREATING HODGKIN LYMPHOMA IN GREECESiskou, O. / Vasilakopoulos, T. / Galanis, P. / Tsirigotis, P. / Batsis, I. / Terpos, E. / Megalakaki, A. / Pouli, A. / Konstantakopoulou, O. / Karagkouni, I. et al. | 2018
-
PCN79 - DECISION IMPACT OF A 21-GENE SIGNATURE IN EARLY BREAST CANCER: A NATURAL EXPERIMENT USING ROUTINE DATATramonti, G. / Gray, E. / Sims, A.H. / Hall, P.S. et al. | 2018
-
PCN57 - THE ASSOCIATION BETWEEN METFORMIN EXPOSURE AND SURVIVAL AMONG DIABETIC PATIENTS WITH NON-SMALL CELL LUNG CANCERRuban, C. / Blanchette, C.M. / Howden, R. / Kowalkowski, M. / Marino, J. / Saunders, W.B. et al. | 2018
-
PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISONCope, S. / Popoff, E. / Keeping, S. / Goldgrub, R. / Jansen, J.P. / Penrod, J.R. / Abraham, P. / Camidge, D.R. / Korytowsky, B. / Gu, T. et al. | 2018
-
PP3 - TUNING INTO WHAT PATIENTS SAY ABOUT CLINICAL TRIALS WHEN SCIENTISTS AND CLINICIANS ARE NOT LISTENING: IMPLICATIONS FOR RECRUITMENTHalhol, S. / Booth, A. / Pan, S. / Cox, A. / Merinopoulou, E. et al. | 2018
-
ND4 - COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON'S DISEASECabout, E. / Kabeshova, A. / Launois, R. / Houeto, J. et al. | 2018
-
PCN171 - A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCERDavies, A.D. / Chang-Douglass, S. et al. | 2018
-
PCV29 - REAL-WORLD DOAC AND VKA USE: THE PHARMO-ANTICOAGULATION COHORTSmits, E. / Evers, J. / Penning-van Beest, F.J. / Herings, R.M. / Bezemer, I.D. et al. | 2018
-
PCV3 - IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINESha'aban, A. / Zainal, H. / Muhamad, A.S. / Hammad, M.A. / Ibrahim, B. et al. | 2018
-
PCV32 - TRENDS IN THE INPATIENT CARE OF CORONARY HEART DISEASE IN 2005-2015Wahler, S. / Koll, C. / Müller, A. et al. | 2018
-
PCP47 - TAMING THE TORNADO CHART: SIMPLIFYING ONE-WAY SENSITIVITY ANALYSES FOR LARGE-SCALE MULTI-PARAMETER MODELSO'Day, K. / Mezzio, D. et al. | 2018
-
PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL?Pisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
-
PCN371 - HEALTH RELATED QUALITY OF LIFE IN CERVIX-UTERI CANCER WOMEN TREATED IN A MEXICAN THIRD LEVEL PUBLIC FACILITYGonzalez-Barba, F. / Sat-Muñoz, D. / Balderas-Peña, L. / Trujillo-Hernández, B. / Martinez-Herrera, B. / Bayardo-López, L.H. / López-Almaraz, L.M. / Salazar-Páramo, M. / Alvarado-Zermeño, A. / Hernández-Chávez, G.A. et al. | 2018
-
PCN337 - HR+/HER2− ADVANCED BREAST CANCER TREATMENT, DISEASE PROGRESSION, AND SURVIVAL IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, AND MEXICOKurosky, S. / Levine, C. / Kaye, J.A. / Esterberg, E. / Suarez, L.A. / Zhan, L. / Iyer, S. et al. | 2018
-
PCP29 - BRAZILIAN PHARMACEUTICAL CLINICAL SERVICES: A DOCUMENTARY ANALYSISChagas, M.O. / Porto, C.C. / Chaveiro, N. / Noll, M. / Assis, D.L. / Chagas, F.A. / Chagas, V.O. et al. | 2018
-
PCN369 - RELATION OF HEALTH RELATED QUALITY OF LIFE WITH INDICATORS OF NUTRITIONAL STATUS IN HEAD AND NECK CANCER PATIENTS ATTENDED IN A MEXICAN THIRD LEVEL PUBLIC FACILITYMartinez-Herrera, B. / Sat-Muñoz, D. / Balderas-Peña, L. / Trujillo-Hernández, B. / Gonzalez-Barba, F. / Solórzano-Meléndez, A. / Bayardo-López, L.H. / Alvarado-Zermeño, A. / Hernández-Chávez, G.A. / Salazar-Páramo, M. et al. | 2018
-
PCN311 - EUROPEAN MARKET ACCESS CHALLENGES FOR RELAPSED REFRACTORY MULTIPLE MYELOMA TRIPLET THERAPIESStefani, I. / Brough, A. / McKee, E. / Lyons, E. et al. | 2018
-
PCN278 - DIVERSITY OF PATIENTS PATHWAYS WITH LUNG CANCER BETWEEN 4 FRENCH REGIONS: DEFINITION OF DISSIMILARITY MEASURESProdel, M. / Blein, C. / Fernandes, J. / Chouaid, C. et al. | 2018
-
PCN130 - COST ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) – A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANYMayerhoff, L. / Lehne, M. / Hickstein, L. / Salimullah, T. / Prieur, S. / Thomas, S.K. / Zhang, J. et al. | 2018
-
PCN118 - THE BURDEN OF CANCER IN SPAINBadia, X. / Tort, M. / Camps, C. / Diaz Rubio, E. et al. | 2018
-
CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATARueda, J. / Valencia, C.F. / Mullins, C.D. / Onukwugha, E. / Zhan, M. / Slejko, J.F. et al. | 2018
-
PCN386 - QUALITY OF LIFE OF CAREGIVERS OF CANCER PATIENTS BEFORE AND AFTER PATIENT ADMISSION TO AN INTENSIVE CARE UNITAl Rabayah, A.A. / Salmany, S. / Al Froukh, R. / AL Rayyan, M. / Al Najjar, B. / Nazer, L. et al. | 2018
-
PCP70 - REGENERATIVE MEDICINE: A PROPOSED CLASSIFICATION FOR HEOR BASED ON THERAPEUTIC STRATEGY AND TECHNOLOGY TYPEPurser, M. / Mladsi, D.M. et al. | 2018
-
PIH40 - THE HEALTH LITERACY OF IRANIAN PARENTS: A SURVEY IN TEHRAN CAPITAL CITYYousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDYAl-Rashidi, A. / Al-Subaie, S.A. / Farooqui, M. et al. | 2018
-
PIH14 - FACTORS ASSOCIATED WITH THE USE OF ANTIPYRETICS IN CHILDREN OF PARENTS IN A COHORT SAMPLE IN SAUDI ARABIAAlmogbel, Y. / AlQussiar, J. et al. | 2018
-
PIH27 - IRANIAN PARENTS' KNOWLEDGE ABOUT ANTIBIOTICSSharif, Z. / Yousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIESAlmasi, T. / Fasseeh, A.N. / Elezbawy, B. / George, M. / Abouelmaged, E. / Arnaiz, F. / Abaza, S.A. / Nagy, B. / Kaló, Z. et al. | 2018
-
PHP123 - REGIONAL DISPARITIES IN THE DISTRIBUTION OF HEALTH CARE FACILITIES: VISUALIZATION OF REGIONAL MEDICAL CARE SUPPORT HOSPITALSShimizu, S. / Shinjo, D. / Sakata, N. / Ishikawa, K.B. / Fushimi, K. et al. | 2018
-
PHP108 - DETERMINANTS OF THE UPTAKE OF ROTAVIRUS AND PNEUMOCOCCAL CONJUGATE VACCINES IN ETHIOPIAWondimu, A. / Postma, M.J. et al. | 2018
-
PHP109 - COST OF UNLICENCED AND ORPHAN MEDICINES IN TURKEY, KAZAKHSTAN AND POLANDAtikeler, K. / Goettsch, W. / Baran, A. / Gaitova, K. / Bayar, B. / Czech, M. / Leufkens, H.G. et al. | 2018
-
PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANYBot, D. / Linstaedt, J. / Ecker, T. et al. | 2018
-
PHP73 - FACTORS INFLUENCING THE DURATION OF MEDICINE PRICE NEGOCIATION IN FRANCEPetri, C. / Holscher, E. / Borget, I. / Bertin, L. et al. | 2018
-
PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANYMathes, J. / Höer, A. et al. | 2018
-
PHP18 - COULD THE ONE-DAY SURGERY PLAY A SIGNIFICANT ROLE IN CATARACT WAITING LIST REDUCTION PROCESS IN HUNGARY?Pónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
-
PHP3 - SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELANDGorry, C. / Hanevy, A. / O'Leary, A. / Tilson, L. / Barry, M. et al. | 2018
-
PGI1 - ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANYWilke, T. / Groth, A. / Long, G.H. / Tatro, A.R. / Sun, D. et al. | 2018
-
PGI34 - A COST SAVING MEASURE FROM THE UTILISATION OF BIOSIMILAR INFLIXIMAB IN THE IRISH SECONDARY CARE SETTINGO'Brien, G.L. / Carroll, D.G. / Walshe, V. / Mulcahy, M. / Courtney, G. / O'Mahony, C. / Byrne, S. et al. | 2018
-
PGI43 - WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
-
PGI29 - GENDER DIFFERENCES IN CLINICAL PROFILE AND HEALTHCARE UTILIZATION OF NON ALCOHOLIC FATTY LIVER PATIENTSGoldshtein, I. / Chodick, G. / Shibolet, O. et al. | 2018
-
PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIESNorrbacka, K. / Divino, V. / Boye, K. / Lebrec, J. / Dekoven, M. et al. | 2018
-
PDB113 - PSYCHOMETRIC EVALUATION OF A SELF-REPORTED MEDICATION ADHERENCE MEASURE ADAPTED TO COMMUNITY PHARMACY PRACTICE : THE QUESTIONNAIRE " TOP SCORE "Michiels, Y. / Bugnon, O. / Vergez, G. / Allaert, F. et al. | 2018
-
PDB104 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF DIABETES IN EGYPTAmin, M. / Abotaleb, A. et al. | 2018
-
PHP338 - PATIENT INVOLVEMENT IN CLINICAL PRACTICE GUIDELINE DEVELOPMENT PROCESSES: DOES REALITY ALIGN WITH INTENT?Desai, B. / Oehrlein, E. / Ganser, T.R. / Ngo, M. / Perfetto, E.M. et al. | 2018
-
PHP322 - REAL-WORLD DATA : WHAT ARE THE USE AND REQUIREMENTS IN HEALTH-ECONOMIC APPRAISALS IN REINSCRIPTION BY THE FRENCH HAUTE AUTORITE DE SANTE (HAS)?Petitjean, A. / Roze, S. et al. | 2018
-
PHP327 - CATEGORISATION OF OBSERVATIONAL STUDIES REQUESTED BY THE EMA AND SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORIZATION STUDIES (PAS)Palacios, L. / De Cock, E. et al. | 2018
-
PHP332 - INTRODUCTION OF MOBILE HEALTH TECHNOLOGY AT THE PRIMARY HEALTHCARE LEVEL IN MONGOLIAChimeddamba, O. et al. | 2018
-
PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?Siering, U. / Özdemir, D. / Thys, S. / Altenhofen, L. / Mischke, C. et al. | 2018
-
PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALSNg, T. / Ziomek, J. / Delaitre-Bonnin, C. / Bending, M.W. et al. | 2018
-
PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATIONBaker, T. / Marinoni, G. / Houslay, D. / Tao, T. / Garbaz, O. / Malhotra, S. et al. | 2018
-
PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANYSchikowski, M. / Gibson, L. / Mrosowsky, T. / Schönermark, M. et al. | 2018
-
PHP219 - MEDICINRÅDET AND THE NEW HOSPITAL DRUG APPRAISAL PROCESS IN DENMARK – THE STORY SO FARRothwell, S. / Macaulay, R. et al. | 2018
-
PHP232 - A COMPARISON OF COST-EFFECTIVENESS ASSESSMENTS BETWEEN NICE AND SMC TECHNOLOGY APPRAISALSGriffiths, E.A. / Hendrich, J. et al. | 2018
-
PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UKWebster, S. / Hau, N. / Ustyugova, A.V. / Kansal, A.R. / Reifsnider, O. et al. | 2018
-
PDB55 - ECONOMIC ANALYSIS OF TYPE-2 DIABETES MELLITUS IN VIETNAM: A RETROSPECTIVE STUDY AT A DISTRICT HOSPITAL, BA RIA - VUNG TAU PROVINCENguyen, T.T. et al. | 2018
-
PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETESMelzer Cohen, C. / Chodick, G. / Nystrup Husemoen, L.L. / Rhee, N.A. / Shalev, V. / Karasik, A. et al. | 2018
-
PDB16 - COMPARE RENAL FUNCTIONAL PRSERVATION OUTCOME OF SGLT2 INHIBITOR VS DPP4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY OF JAPANESE COMMERCIAL DATABASE WITH ADVANCED ANALYTICS APPROACHZhou, F.L. / Watada, H. / Tajima, Y. / Berthelot, M. / Kang, D. / Esnault, C. / Shuto, Y. / Maegawa, H. / Koya, D. et al. | 2018
-
PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTSLavikainen, P.T. / Hartikainen, J. / Miettinen, H. / Viljakainen, M. / Martikainen, J.A. / Tolppanen, A. / Roine, R.P. et al. | 2018
-
PDB8 - FACTORS ASSOCIATED WITH UNCONTROLLED GLYCEMIA AMONG OUTPATIENTS WITH TYPE 2 DIABETESHammad, M.A. / Syed Sulaiman, S.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCELanitis, T. / Bregman, B. / Maunoury, F. / Prawitz, T. / Gaudin, A. / Cotté, F. et al. | 2018
-
PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE: A SYSTEMATIC REVIEWKumar, S. / Loh, F.E. et al. | 2018
-
PCV63 - ECONOMIC BURDEN ASSOCIATED WITH SECONDARY CARDIOVASCULAR (CV) EVENTS – A SYSTEMATIC LITERATURE REVIEWCholasamudram, S. / Yenamandra, J. / Jindal, R. / Cristino, J. et al. | 2018
-
PCN223 - WHAT UNDERLIES THE OBSERVED HOSPITAL VOLUME-OUTCOME RELATIONSHIP?Huguet, M. / Joutard, X. / Ray-Coquard, I. / Perrier, L. et al. | 2018
-
PCN239 - NICE AND THE CANCER DRUGS FUND: APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLANDEdwards, H.K. / Kent, E. / Landells, L.J. et al. | 2018
-
PCN228 - REAL-WORLD USE OF PEMBROLIZUMAB AND NIVOLUMAB FROM CLINICAL TRIALS TO MARKET LAUNCH: WHAT CAN BE LEARNED?Bouee Benhamiche, E. / Le Bihan Benjamin, C. / Rocchi, M. / Negellen, S. / Bousquet, P.J. et al. | 2018
-
PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANYEscalada, J. / Bonnet, F. / Wu, J. / Bonnemaire, M. / Gupta, S. / Cambron-Mellot, M.J. / Nicholls, C. / Müller-Wieland, D. et al. | 2018
-
PCN217 - KEEPING UP WITH THE COMPARATORS: TRENDS IN TARGETED CANCER THERAPIES BECOMING RIGHT COMPARATORS FOR PAYERSWijnands, T. / Strydom, M. / Spinas, N. / van Engen, A. et al. | 2018
-
PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTSBellone, M. / Pradelli, L. / Masetti, L. / Recchia, A. / Orfanos, P. et al. | 2018
-
PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIRNuñez Alfonsel, J. / Hidalgo, A. / Ielpo, B. / Quijano, Y. / Vicente, E. et al. | 2018
-
PCN135 - DOES PATIENT SELECTION CRITERIA TRANSLATE INTO COST SAVINGS IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY FAILURE IN SPAIN?Ramon, A. / Paladio, N. / Male, N. et al. | 2018
-
PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGALGuerreiro, R. / Miguel L, Silva / Costa, J. / Paquete, A.T. / Alarcão, J. / Fiorentino, F. / Borges, M. et al. | 2018
-
PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBECPettigrew, M. / Garces, K. et al. | 2018
-
PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMASiskou, O. / Terpos, E. / Galanis, P. / Vasilakopoulos, T. / Tsirigotis, P. / Batsis, I. / Megalakaki, A. / Pouli, A. / Konstantakopoulou, O. / Karagkouni, I. et al. | 2018
-
PCN104 - ECONOMIC ANALYSIS OF COSTS AND RESOURCE CONSUMPTION OF IXAZOMIB IN PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA IN AUSTRIAWalter, E. / Lazic-Peric, A. / Schalle, K. / Voit, M. et al. | 2018
-
PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINAZhang, Y. / Samuelsen, C.H. / Griebsch, I. / Yao, Z. et al. | 2018
-
PCN61 - REAL-WORLD PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANYCizova, D. / Gottschalk, F. / Mueller, S. / Myers, D. / Wilke, T. et al. | 2018
-
PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHINGGurskyte, L. / Muresan, B. / Kulakova, M. / Postma, M.J. / Ouwens, M.J. / Heeg, B. et al. | 2018
-
PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMABregman, C. / Supiot, R. / Pacou, M. / Doan, J. / Dale, P. / Malcolm, B. et al. | 2018
-
QL2 - HEALTH UTILITY OF PATIENTS WITH TYPE 2 DIABETES AND VARIOUS SINGLE AND MULTIPLE COMPLICATIONS IN CHINA: A NATIONWIDE SURVEYWang, P. / Li, C. et al. | 2018
-
PCN14 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATESDaSilva, C. / Noone, J.M. / Wriede, V. et al. | 2018
-
QL1 - VALIDATION OF PROMIS PREFERENCE SCORE (PROPR) IN GERMAN PATIENTS WITH RHEUMATOLOGICAL CONDITIONSKlapproth, C.P. / Obbarius, A. / Merbach, M. / Rose, M. / Fischer, F. et al. | 2018
-
PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATIONRyazhenov, V.V. / Gorokhova, S.G. / Gorokhov, V. et al. | 2018
-
PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES: A NATIONWIDE POPULATION-BASED COHORT STUDYYun, J.E. et al. | 2018
-
PCV27 - HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANYWachter, R. / Klebs, S. / Balas, B. / Kap, E.J. / Engelhard, J. / Schlienger, R. / Fonseca, A.F. / Proenca, C.C. / Bruce Wirta, S. et al. | 2018
-
PCP68 - MEDICAL ACCESS STRATEGY TO IMPROVE ACCESS TO INNOVATIVE AND EXPENSIVE THERAPY IN FRANCECohen, S. / Paubel, P. / Monchecourt, F. et al. | 2018
-
PCP69 - APPLICATION DECREE OF JARDE LAW: EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCEGuillemot, J. / Syed, I.A. / Jamet, N. et al. | 2018
-
PCP37 - THE CONFIDENTIALITY REGARDING DRUGS PRICING AND REIMBURSEMENT IN ROMANIAPaveliu, M.S. / Radu, P. et al. | 2018
-
PCN375 - ASSESSING NUTRITIONAL STATUS AMONG PATIENTS WITH LUNG CANCERPakai, A. / Istlstekker, I. / Vajda, R. / Csákvári, T. / Váradyné Horváth, Á. / Póhr, K. / Fusz, K. / Boncz, I. / Oláh, A. et al. | 2018
-
PCN359 - COMPARISON OF INSTITUTIONAL AND HOME HOSPICE CAREDeleróza, A. / Fusz, K. / Pusztai, D. / Csákvári, T. / Váradyné Horváth, Á. / Á, Müller / Boncz, I. / Oláh, A. et al. | 2018
-
PCN317 - THE CANCER DRUGS FUND: KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SETLatimer, N.R. et al. | 2018
-
PCN305 - NICE AND THE CANCER DRUGS FUND – CAN OBSERVATIONAL EVIDENCE INFORM FUNDING DECISIONS IN ONCOLOGY?Walsh, S. / Liu, L.W. / Macaulay, R. et al. | 2018
-
PCN289 - HOW ACCELARATED IS PATIENTS' ACCESS TO NEW ONCOLOGY PRODUCTS IN THE NEW ERA OF CANCER DRUG'S FUND IN ENGLAND?Bates, B.E. / Tsoumani, E. et al. | 2018
-
PCN332 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIESAnjo, J. / Rider, A. / Bailey, A. / Gaudig, M. et al. | 2018
-
PCN287 - ANALYSIS OF IMPACTS OF THE SUPPLEMENTARY SCHEMES ON THE DRUG REIMBURSEMENT DECESION-MAKING UNDER THE POSITIVE LIST SYSTEM IN KOREAK.I.M., T. et al. | 2018
-
AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIAWasir, R. / Irawati, S. / Makady, A. / Postma, M.J. / Goettsch, W. / Feenstra, T. / Buskens, E. et al. | 2018
-
PCN339 - SPEAR-BLADDER (STUDY INFORMING TREATMENT PATHWAY DECISION IN BLADDER CANCER): TIMING OF TREATMENT FOLLOWING FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC UROTHELIAL CANCER IN THE COMMUNITY ONCOLOGY SETTING IN THE UNITED STATESDoshi, G. / Bhanegaonkar, A. / Bharmal, M. / Phatak, H. / Boyd, M. / Aguilar, K.M. / Kearney, M. et al. | 2018
-
CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTIONDong, O. / Lee, C.R. / Wheeler, S.B. / Voora, D. / Dusetzina, S.B. / Wiltshire, T. et al. | 2018
-
AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL CONDITIONS (2015-2018)Lidonnici, D. / Lanati, E.P. / Niedecker, S. / Isernia, M. / Ronco, V. et al. | 2018
-
CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALSWang, S.V. / Schneeweiss, S. / Gagne, J.J. / Evers, T. / Gerlinger, C. / Desai, R. / Najafzadeh, M. et al. | 2018
-
PDB137 - COMPARISON OF ORAL ANTIDIABETIC DRUGS AS ADD-ON TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON METFORMIN: A NETWORK META-ANALYSISSitu, B. et al. | 2018
-
PGI52 - DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDYKnight, A. / Balp, M. / Mckenna, S.J. / Przybysz, R. / Cai, J. / Brass, C. / Howe, T. / Rosen, D. / Gavaghan, M. / Vazquez, V.C. et al. | 2018
-
PIN20 - A COST-EFFECTIVENESS ANALYSIS OF THE INFLUENZA VACCINE IN ADULT PATIENTS WITH CANCERShields, G.E. / Cranmer, H. / Camacho, C. / Porter, J.K. et al. | 2018
-
PIN22 - A PAYER PERSPECTIVE OF THE HOSPITAL INPATIENT ADDITIONAL CARE COSTS OF ANTIMICROBIAL RESISTANCE IN FRANCE: A MATCHED CASE-CONTROL STUDYTouat, M. / Brun-Buisson, C. / Opatowski, M. / Cosker, K. / Guillemot, D. / Salomon, J. / Tuppin, P. / de Lagasnerie, G. / Watier, L. et al. | 2018
-
PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAINMira-Iglesias, A. / Baselga-Moreno, V. / López-Labrador, F.X. / Díez-Domingo, J. et al. | 2018
-
PIH51 - THE EFFECT OF EXERCISING ON SEXUAL FUNCTIONS IN POST-MENOPAUSAL WOMENNovák, E. / Oláh, A. / Vajda, R. / Csákvári, T. / Boncz, I. / Ferenczy, M. / Kiss, T. / Radics, L. / Pakai, A. et al. | 2018
-
PIH29 - DEVELOPMENT OF A DECISION AID PROTOTYPE FOR PARENTS CONSIDERING TUBE FEEDING FOR THEIR CHILDRENRivero, C. / Rodriguez, A. / Moreno, A. / Vives, I. / Layola, M. / Gabás-Rivera, C. / Aceituno, S. et al. | 2018
-
PIH34 - PROGRAM 75+ - FREE MEDICINES FOR THE ELDERLYPlisko, R. / Rutkowski, J. et al. | 2018
-
PIH30 - ASSESSMENT OF TREATMENT PATTERN IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A TERTIARY CARE HOSPITAL IN URBAN SETTINGKrishna Murthy, M. / Ravi, R. / Jose, S.A. / Pudi, C. / Koonisetty, K.S. / Minnikanti, S.S. et al. | 2018
-
PIN5 - 10 YEARS OF HUMAN PAPILLOMAVIRUS SYSTEMATIC VACCINATION IN SPAIN: FORECASTING HEALTH OUTCOMES CONSIDERING AS04-HPV16/18 VACCINE EFFECTIVENESS DATAMorano, R. / Cambronero, Md / López Sanromá, M. et al. | 2018
-
PIH21 - BUDGET IMPACT OF A NEW INTRAUTERINE SYSTEM IN PORTUGALMaia-Lopes, S. / Pissarra, M. / André, S. et al. | 2018
-
PIH6 - DEVELOPMENT AND VALIDATION OF A SCREENING QUESTIONNAIRE TO DETECT HEAVY MENSTRUAL BLEEDING IN GYNAECOLOGY: THE SAMANTA QUESTIONNAIRERius, J. / Carrasco, M. / Pujol, P. / Catafal, G. / Perelló, J. / Calaf, J. et al. | 2018
-
PIH11 - ANTIEMETIC USE IN PREGNANCY AND THE RISK OF MAJOR CONGENITAL MALFORMATIONS: A POPULATION-BASED COHORT STUDYBérard, A. / Sheehy, O. / Gorgui, J. / Zhao, J. / Moura, C. / Bernatsky, S. et al. | 2018
-
PHP218 - HOW HIGH CAN YOU GO? - THE IMPACT OF INDICATION EXPANSION AND MARKET COMPETITION ON DRUG PRICES IN THE EU5Radu, X. / Damera, V. / Martin, M. et al. | 2018
-
PHP201 - DEVELOPMENT OF MEDICATION SAFETY STANDARDS IN SELECTED HOSPITALS IN IRANIzadpanah, F. / Nikfar, S. / Bakhshi Imcheh, F. / Zargaran, M. et al. | 2018
-
PHP208 - PHYSICIANS' IMPROVEMENT SUGGESTIONS FOR ENTERAL NUTRTION CARE IN CHINA: A CROSS-SECTIONAL SURVEYSuo, S. / Ung, C.O. / Shi, H. / Chen, S. / Hu, H. et al. | 2018
-
PHP150 - GEOGRAPHICAL VARIABILITY IN THE UTILIZATION OF SERVICES AND PHARMACEUTICAL EXPENDITURE BY ADVANCED CHRONIC PATIENTSDíaz-Carnicero, J. / Uso-Talamantes, R. / Bertomeu-Izquierdo, L. / Trillo Mata, J.L. / Vivas, D. et al. | 2018
-
PHP153 - KEY STAKEHOLDERS PERCEPTIONS OF HEOR USAGE IN LEBANONMesmar, A. / Maskineh, C. / Becker, R.V. et al. | 2018
-
PHP146 - ANALYSES OF THE PERFORMANCE INDICATORS OF REHABILITATION AND CHRONIC INPATIENT CARE IN HUNGARY BETWEEN 1990 AND 2016Ágoston, I. / Endrei, D. / Molics, B. / Szarka, E. / Gyuró, M. / Komáromy, M. / Boncz, I. et al. | 2018
-
PHP133 - TOWARDS IMPLEMENTING MEDICATION THERAPY MANAGEMENT SERVICE IN MALAYSIA: PERCEPTIONS AND CHALLENGESAl-Tameemi, N.K. / Sarriff, A. et al. | 2018
-
PHP116 - TREND IN OPIOID USE FROM 2001 THROUGH 2013 AMONG ELDERLY US VETERANSDwibedi, N. / Rowneki, M. / Shen, C. / Helmer, D. / Sambamoorthi, U. et al. | 2018
-
PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE: REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASESVeronesi, C. / Biancone, L. / Burra, P. / De Simone, P. / Grandaliano, G. / Rigotti, P. / Tisone, G. / Perrone, V. / Degli Esposti, L. et al. | 2018
-
PHP80 - HOW CLASSIFICATION OF CELL AND GENE THERAPIES AS DRUGS, DEVICES OR PROCEDURES COULD HAVE SIGNIFICANT IMPLICATIONS FOR THEIR PRICING AND REIMBURSEMENT AND COMMERCIAL SUCCESSMacaulay, R. / Wang, G.D. / Rothwell, S. et al. | 2018
-
PHP58 - SPANISH THERAPEUTIC POSITIONING REPORTS: 6-YEAR UPDATE – INCREASING IN FREQUENCY BUT NOT RELEVANCE?Macaulay, R. / Fernandez Dacosta, R. et al. | 2018
-
PHP65 - ANALYSIS OF ICER-ESTIMATED VALUE-BASED PRICES AND POTENTIAL DISCOUNTS FOR DRUGS IN THE UNITED STATESKloc, K. / Dusza, M. / Lach, S. / Sediri, Y. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP50 - PRICE REGULATION ORDINANCE IMPACT ON REIMBURSED PRICES FOR MOSTLY PRESCRIBED MEDICINES IN BOSNIA AND HERZEGOVINAČatić, T. / Jusufović, R. / Tabakovic, V. et al. | 2018
-
PHP21 - METHODOLOGY OF IDENTIFICATION OF RISK GROUPS UNDER PHARMACEUTICAL GUIDELINES IN A SPECIAL REGIME INSURER IN COLOMBIARomero, M. / Gallo, D. / Silva, E. et al. | 2018
-
PHP47 - EVALUATING PATIENTS', PHYSICIANS' AND PHARMACISTS' PERCEPTION REGARDING GENERIC MEDICINES IN GONDAR, NORTHWEST ETHIOPIAGebresillassie, B.M. et al. | 2018
-
PHP30 - THE CONTRIBUTION OF NEW PRODUCT ENTRY VS EXISTING PRODUCT INFLATION IN THE RISING COSTS OF PRESCRIPTION DRUGS IN THE UNITED STATESHernandez, I. / Good, C.B. / Cutler, D. / Gellad, W.F. / Parekh, N. / Shrank, W.H. et al. | 2018
-
PGI33 - URSODEOXYCHOLIC ACID TO GALLSTONE DISSOLUTION THERAPY IN ASYMPTOMATIC CHOLELITHIASIS PATIENTS: A SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETYSenna, K. / Santos, M. / Parreira, V. et al. | 2018
-
PGI23 - COST-EFFECTIVENESS ANALYSIS OF PARENTERAL METHOTREXATE FOR THE TREATMENT OF CROHN'S DISEASE IN THE CZECH REPUBLICMlcoch, T. / Hajickova, B. / Ornstová, E. / Chadimova, K. / Bartakova, J. / Dolezal, T. et al. | 2018
-
PDB127 - APPLICATION OF BEST WORST SCALING TO IMPROVE PATIENT-CENTERED TREATMENT DECISIONS IN DIABETIC PERIPHERAL NEUROPATHYAdams, A.S. / Prosser, L. / Altschuler, A. / Ma, L. / Wittenberg, E. et al. | 2018
-
PDB103 - FINANCIAL ACCESS TO HEALTH CARE USE IN DIABETICS WITH HIGH-DEDUCTIBLE HEALTH PLAN (HDHP)Yao, J. / Li, M.S. / Lu, K. et al. | 2018
-
PDB134 - CHARACTERISTICS OF US ADULTS WITH CONTROLLED AND UNCONTROLLED TYPE 2 DIABETESMorlock, A. / Dobrescu, R. et al. | 2018
-
PHP352 - SUCCESS FACTORS FOR THE IMPLEMENTATION OF MARKET ACCESS AGREEMENTS IN EMERGING MIDDLE-INCOME MARKETS IN PREPARATION FOR OUTCOMES BASED CONCEPTSBayard, J.K. / Gretsch, K. / Hallal, Z. / Stojkovic, N.S. / Strydom, J. et al. | 2018
-
PHP339 - MINIMALLY IMPORTANT DIFFERENCE (MID) OF EQ-5D-5L INDEX SCORE IN HONG KONG ADULTS POPULATION USING HONG KONG SCORING ALGORITHMWong, E.L. / Cheung, A.W. / Yau, P.S. / Wong, A.Y. / Xu, H. / Ramos Goñi, J.M. / Rivero-Arias, O. et al. | 2018
-
PHP336 - THE PRESCRIPTION COST ANALYSIS AS A TOOL TO INFORM HEALTHCARE RESOURCE ALLOCATION AND ACCESS TO PHARMACEUTICALS IN ENGLANDJohnson, K.I. / Jones, C. / Zabala Mancebo, J. et al. | 2018
-
PHP311 - UPTAKE OF JOINTLY PRODUCED EUNETHTA HEALTH TECHNOLOGY ASSESSMENTS: WHERE ARE WE NOW?Garrett, Z. et al. | 2018
-
PHP310 - COMPARISON OF THE HEALTH TECHNOLOGY ASSESSMENT OFFICES OF HUNGARY AND POLAND BASED ON OBJECTIVE CRITERIANemeth, B. / Krupa, D. / Staniak, A. / Józwiak-Hagymásy, J. / Vokó, Z. et al. | 2018
-
PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIESCsanádi, M. / Inotai, A. / Németh, B. / Oleshchuk, O. / Lebega, O. / Brodovskaya, A. / Piniazhko, O. / Kaló, Z. et al. | 2018
-
PHP273 - A REVIEW OF ISSUES AFFECTING THE EFFICIENCY OF DECISION MAKING IN THE NICE SINGLE TECHNOLOGY APPRAISAL PROCESSWalton, M.J. / O'Connor, J. / Carroll, C. / Biswas, M. / Claxton, L. / Hodgson, R. et al. | 2018
-
PHP259 - PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIESMihajlovic, J. / Yeğenoğlu, S. / Sozen Sahne, B. / Postma, M. et al. | 2018
-
PHP226 - VALUE-BASED PRICING WHEN THE VALUE DIFFERS BETWEEN INDICATIONS – WHAT IS THE GERMAN WAY?Witte, J. / Greiner, W. et al. | 2018
-
PDB96 - APPLYING MCDA FRAMEWORK IN PHARMACEUTICAL POLICY DECISION MAKING: A PILOT STUDY IN DIABETES MELLITUS TYPE 2Comellas, M. / Santiago, C. / Gasol, M. / Navarro, J. / Uso-Talamantes, R. / Fernandez, I. / Lizán, L. et al. | 2018
-
PDB49 - TYPE 2 DIABETES MELLITUS IN ALGERIA – A COST OF ILLNESS STUDYOulad abdallah, R. / Boukana, R. / Loumi, W. / Nebchi, E. / Mimene, A. et al. | 2018
-
PDB44 - THE HEALTH ECONOMIC VALUE OF SHORT-TERM CARDIOVASCULAR BENEFITS ASSOCIATED WITH SGLT-2I FROM CVD-REALWard, T. / Bennett, H. / McEwan, P. / Edmonds, C. / Kartman, B. / Fenici, P. / Thuresson, M. / Kosiborod, M. et al. | 2018
-
PDB3 - THE IMPACT OF GLYCATED HEMOGLOBIN CONTROL ON MORBIDITY AND SURVIVAL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Qamar, M. / Shaikh, F.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLANDCarroll, R. / Lambrelli, D. / Donaldson, R. / Schultze, A. / Nordstrom, B. / Stynes, G. / Ramagopalan, S. / Alikhan, R. et al. | 2018
-
PCV121 - PERFORMANCE INDICATORS OF CARDIAC REHABILITATION IN HUNGARYEndrei, D. / Sebestyén, A. / Ágoston, I. / Csákvári, T. / Kovács, G. / Nogel, M. / Boncz, I. et al. | 2018
-
PCV126 - A COST-EFFECTIVENESS THRESHOLD BASED ON THE MARGINAL RETURNS OF CARDIOVASCULAR HOSPITAL SPENDINGvan Baal, P. / Perry-Duxbury, M. / Bakx, P. / Versteegh, M. / van Doorslaer, E. / Brouwer, W. et al. | 2018
-
PCV101 - HYPERTRIGLYCERIDEMIA AND RISK OF ALL-CAUSE MORTALITY AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) EVENTS IN CLINICAL PRACTICE: THE TG-REAL STUDYVeronesi, C. / Arca, M. / Borghi, C. / Colivicchi, F. / De Ferrari, G. / Desideri, G. / Pontremoli, R. / Temporelli, P. / Perrone, V. / Degli Esposti, L. et al. | 2018
-
PCV105 - POTENTIAL REDUCTION IN MORTALITY AND HOSPITALISATIONS WITH OPTIMAL USAGE OF SACUBITRIL/VALSARTAN THERAPY FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN IRELANDO'Brien, S. / Sweeney, C. / Carney, P. et al. | 2018
-
PCV94 - NUTILIS CLEAR® IN DYSPHAGIC ADULT STROKE PATIENTS WITH ASPIRATION OF 10–14 POINTS ON GUSS SCALEPelczarska, A. / Jakubczyk, M. / Niewada, M. / Lipka, I. et al. | 2018
-
PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPOREDeclan, L. / Tang, Z.X. / Ng, C. / Tan, J. / Trueman, D. / Woodcock, F. / Cristino, J. et al. | 2018
-
PCV93 - COST-EFFECTIVENESS OF GUIDELINE ADHERENCE IN CORONARY PATIENTS: THE IMPACT OF THE METHODOLOGYDe Smedt, D. / Annemans, L. / Kotseva, K. / Wood, D. / De Backer, G. / Rydén, L. / De Bacquer, D. et al. | 2018
-
PCV79 - REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCEBowrin, K. / Briere, J. / Millier, A. / Levy, P. / Clay, E. / Toumi, M. et al. | 2018
-
PCN243 - POST-LOE PRICING DYNAMICS IN ONCOLOGY: IMPACT OF MANDATORY PRICE DISCOUNTS ON LIST PRICES AND GENERIC UPTAKESeitlinger, J. / Flostrand, S. et al. | 2018
-
PCN271 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BREAST CANCER IN SPAINCallejo-Velasco, D. / Gómez-Navarro, V. / Solozabal, M. / Planellas, L. / Carreño-Serra, A. / Á, Baltasar-Sanchez et al. | 2018
-
PCN265 - END OF LIFE CANCER CHEMOTHERAPY: A RETROSPECTIVE STUDY DURING INTENSIVE CARE UNIT (ICU) STAYReis Neto, J.P. / Busch, J.M. et al. | 2018
-
PCN229 - COMPARISON OF SICKNESS BENEFIT AND SICK LEAVE DURATION IN ONCOLOGY ACROSS COUNTRIESContente, M. / Singh, P. / Smela-Lipińska, B. / van Dijk, B. / François, C. et al. | 2018
-
PCN247 - TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) POST PLATINUM-BASED THERAPY (PPBT) IN THE IMMUNO-ONCOLOGY (IO) ERARadtchenko, J. / Korytowsky, B. / Abraham, P. / Singh, P. / Feinberg, B.A. et al. | 2018
-
PCN202 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN BREAST CANCER PATIENTSChung, J. / Merritt, N. / Kish, J. / Nabhan, C. / Feinberg, B.A. et al. | 2018
-
PCN219 - CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE: RETROSPECTIVE ANALYSIS FROM LEEDS CANCER CENTRECheeseman, S. / Thompson, M. / Riaz, M. / Twelves, C. / Perren, T. / Ahat-Donker, N. / Sopwith, W. / Myland, M. / Lee, A. / Przybysz, R. et al. | 2018
-
PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDSLeeneman, B. / Franken, M. / Aarts, M.J. / van Akkooi, A.C. / van den Berkmortel, F.W. / van den Eertwegh, A.J. / de Groot, J.W. / Herbschleb, K.H. / van der Hoeven, K.J. / Hospers, G.A. et al. | 2018
-
PCN185 - COST-EFFECTIVENESS OF NIVOLUMAB IN SECOND-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA IN ADULTS AFTER FAILURE OF PRIOR PLATINUM-CONTAINING THERAPY IN GREECEBoukouvalas, S. / Diamantogiannis, F. / Basta, E. / Stephens, S. et al. | 2018
-
PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDSKlijn, S. / Van de Wetering, G. / Malcolm, B. / Dale, P. / Pompen, M. / Stevanovic, J. et al. | 2018
-
PCN162 - DENOSUMAB VERSUS BISPHOSPHONATES FOR THE TREATMENT OF BONE METASTASES FROM SOLID TUMORS: A SYSTEMATIC REVIEW OF ECONOMIC STUDIESMatuoka, J. / Kahn, J. / Secoli, S.R. et al. | 2018
-
PCN156 - PHARMACOECONOMICS OF NIMOTUZUMAB IN PATIENTS WITH HEAD AND NECK CANCER IN CUBAPérez, L. / Collazo, M.M. / Iznaga, N. / García, A. et al. | 2018
-
PCN149 - COST-EFFECTIVENESS OF BRCA1/2 MUTATION PROFILING TO TARGET OLAPARIB USE IN PATIENTS WITH METASTATIC BREAST CANCER IN JAPANSaito, S. / Nakazawa, K. / Nagahashi, M. / Akazawa, K. et al. | 2018
-
PCN137 - THE ECONOMIC EVALUATION OF IMATINIB COMBINED WITH CHEMOTHERAPY FOR PEDIATRIC PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINAWang, V.W. / Li, Z. et al. | 2018
-
PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREAKim, S. / Han, S. / Kim, H. / Suh, H.S. et al. | 2018
-
PCN109 - EVALUATION OF THE FACTORS AFFECTING THE COST OF PALLIATIVE CARE AT A UNIVERSITY HOSPITALSozmen, M.K. / Koç, E.M. / C.A.N., H. / Kaplan, Y.C. et al. | 2018
-
PCN68 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLANDHollmann, S. / Painter, C. / Hogan, A. / Wickstead, R.M. / Goyert, N. / Patel, S. / Slowley, A. / Jousseaume, E. / El Ouagari, K. / Zhang, J. et al. | 2018
-
PCN65 - LONG- TERM SURVIVAL AMONG PATIENTS WITH HIGH-GRADE GLIOMA TREATED WITH NIMOTUZUMABSanchez, L. / Lorenzo-Luaces, P. / Viada Gonzalez, C. et al. | 2018
-
PCN32 - THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A RETROSPECTIVE COHORT STUDYAl Rabayah, A.A. / Hammoudeh, S. / Mashni, O. / Hanoun, E. / Al Qasem, W. / AL momani, D. et al. | 2018
-
PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONSMuresan, B. / Hu, Y. / Postma, M.J. / Ouwens, M.J. / Heeg, B. et al. | 2018
-
PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE: MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGYZheng, Y. / Lanitis, T. / Ambavane, A. / Proskorovsky, I. / Bharmal, M. / Phatak, H. et al. | 2018
-
PCN11 - GLOBAL LONGITUDINAL ASSESSMENT OF TREATMENT OUTCOMES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (GLANCE-H&N) STUDYGruenwald, V. / Chirovsky, D. / Cheung, W. / Bertolini, F. / Ahn, M. / Yang, M. / de Castro, G. / Berrocal, A. / Sjoquist, K. / Kuyas, H. et al. | 2018
-
DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES: A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIALBennett, H. / McEwan, P. / Evans, M. / Tank, A. et al. | 2018
-
PCV25 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYGazzi, L. / Fanelli, F. / Heiman, F. / Di Filippo, A. / Pegoraro, V. et al. | 2018
-
PCV59 - HEALTH INSURANCE COST OF ESSENTIAL (PRIMARY) HYPERTENSION IN HUNGARY: A NATIONWIDE, REAL-WORLD COST OF ILLNESS STUDYEndrei, D. / Sebestyén, A. / Gazsó, T. / Zemplényi, A. / Gratz, B. / Boncz, I. et al. | 2018
-
PCV47 - PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONSZyryanov, S. et al. | 2018
-
PCV56 - CLINICAL AND ECONOMIC BURDEN OF CARDIOVASCULAR DISEASE AND VALUE OF EVOLOCUMAB TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN SWEDENHaines, P. / Sorio-Vilela, F. / Sandelin, R. / Villa, G. et al. | 2018
-
PCP63 - DETERMINING THE OPTIMAL COST-EFFECTIVENESS CUTOFF FROM FIRST PRINCIPLES OF ECONOMICSPhelps, C.E. et al. | 2018
-
PCV19 - PATTERNS OF ANTICOAGULATION CONTROL AND CLINICAL OUTCOMES IN ATRIAL FIBRILLATION PATIENTS TREATED WITH VITAMIN K ANTAGONISTS: A REAL-WORLD STUDY USING POPULATION-BASED DATA AND GROUP-BASED TRAJECTORY MODELSGarcia-Sempere, A. / Santaana, Y. / Rodriguez-Bernal, C. / Sanfelix, G. / Peiro, S. et al. | 2018
-
PCV11 - MODELING CARDIOVASCULAR EVENT REDUCTION THROUGH LOW-DENSITY LIPOPROTEIN REDUCTION IN COST-EFFECTIVENESS ANALYSES: A META-REGRESSION APPROACHDi Tanna, G.L. / Villa, G. et al. | 2018
-
PCV1 - NERVOUS SYSTEM DRUGS AND RISK OF ISCHEMIC STROKE: A REAL WORLD DATA CASE-CONTROL STUDYGomez-Lumbreras, A. / Giner, M. / Marsal, J. / García-Sangenis, A. / Pera, H. / Morros, R. et al. | 2018
-
PCP61 - EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICEDoyle, J.J. / Wood, B. et al. | 2018
-
PCP53 - A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATIONDenysyk, L. / Doyle, J. / Sood, R. et al. | 2018
-
PCP55 - REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGYJulian, G.S. / Duva, A. / Santana, P. / Cavalcanti, H.E. / Ballalai, A.F. et al. | 2018
-
PCP56 - EARLY ACCESS PROGRAMS: RECOMMENDATIONS FOR REAL-WORLD DATA COLLECTIONStein, D. / Soni, M. et al. | 2018
-
PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?Dabbous, M. / Rémuzat, C. / Dussart, C. / Toumi, M. et al. | 2018
-
PCP22 - KILL / REPLACE / REGULATE: MOLECULAR-LEVEL VIEW OF TREATING DISEASE, EMERGING SOLUTIONS AND IMPLICATIONS FOR THE FUTURE OF HEALTHCARESogokon, P. / Morrison, S. et al. | 2018
-
PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT: A MARKER OF HTA FAILURE?Pisarczyk, K. / Rémuzat, C. / Hajjeji, B. / Toumi, M. et al. | 2018
-
PCP5 - THE ECOLOGICAL AND SOCIAL COSTS AND BENEFITS OF INTERVENTIONS – USING THE PRODUCT CARBON FOOTPRINT IN VALUE ASSESSMENTMiltenburger, C. / Borgstrom, F. / Ortsater, G. et al. | 2018
-
PCP11 - ORGANISATIONAL MODELS AND OPPORTUNITIES FOR EFFICIENCY MEASURING IN HEALTH CAREAraja, D. et al. | 2018
-
PCP44 - IMPLICATIONS OF GENOME-DRIVEN ONCOLOGY ON EVIDENCE REQUIREMENTS FOR HEALTH TECHNOLOGY ASSESSMENTLeslie, I. et al. | 2018
-
PCN364 - EVALUATING PSYCHOMETRIC PROPERTIES OF UK EQ-5D-5L SCORING ALGORITHMS IN METASTATIC MERKEL CELL CARCINOMABharmal, M. / Hunger, M. / Schlichting, M. et al. | 2018
-
PCN365 - AN ASSESSMENT OF PATIENT REPORTED OUTCOME (PRO) CLINICAL TRIAL DATA REPORTING, SPECIFIC TO CHOLANGIOCARCINOMA (CCA)Bernarde, J. / Boxell, E. / Baldock, L. / Rylands, A.J. et al. | 2018
-
PCN304 - APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA – A DYNAMIC SITUATIONItalia, N. / Kossow, S. / Claes, A. / Templin, C. / Kulp, W. et al. | 2018
-
PCN318 - CONDUCTING AND REPORTING INDIRECT TREATMENT COMPARISONS: A CRITICAL APPRAISAL OF ONCOLOGY TECHNOLOGY APPRAISALSLangham, J. / Langham, S. et al. | 2018
-
PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU: A PERSPECTIVE FROM REGULATORS AND PAYERSFonseca, A.F. / Deplazes, S.N. et al. | 2018
-
HT7 - A REVIEW OF EFFICIENCY OPINIONS OF FRENCH 'HAUTE AUTORITE DE SANTE' (HAS) IN THE ONCOLOGY FIELDGalasso, A. / Diaz A, Medina / Cotté, F. / Gaudin, A. et al. | 2018
-
CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCEChouaid, C. / Bensimon, L. / Clay, E. / Millier, A. / Lévy-Bachelot, L. / Huang, M. / Levy, P. et al. | 2018
-
CE3 - COST-EFFECTIVENESS OF DEMENTIA CARE MANAGEMENT ALONGSIDE A CLUSTER-RANDOMIZED CONTROLLED INTERVENTIONAL DELPHI TRIALMichalowsky, B. / Xie, F. / Kaczynski, A. / Hoffmann, W. et al. | 2018
-
AC4 - RETROSPECTIVE ANALYSIS OF INAPPROPRIATE MEDICATION PRESCRIPTION INDICATORS IN ELDERLY POPULATION IN ITALYGalimberti, F. / Casula, M. / Olmastroni, E. / Russo, V. / Piscitelli, A. / Orlando, V. / Menditto, E. / Tragni, E. et al. | 2018
-
AD4 - ARE PATIENT-REPORTED PERSISTENCE AND ADHERENCE TO TREATMENT FOR A CHRONIC DISEASE VALID OUTCOMES? AN EXAMPLE WITH OSTEOPOROSISSenay, A. / Perreault, S. / Delisle, J. / Morin, S.N. / Banica, A. / Laflamme, Y. / Leduc, S. / Mac-Thiong, J. / Ranger, P. / Rouleau, D. et al. | 2018
-
PCN322 - AN EXAMPLE OF RWE USED FOR HTA EVALUATION: ERLOTINIB RENEGOTIATION IN ITALYRecchia, A. / Gervasi, A. / Avitabile, A. / Greco, A. et al. | 2018
-
CN1 - VALIDATING SURVIVAL EXTRAPOLATIONS IN FIRST LINE TREATMENT OF RENAL CELL CARCINOMA USING LITERATURE-BASED CONDITIONAL SURVIVAL PROBABILITIESKlijn, S. / Hofstra, M. / Malcolm, B. / Johannesen, K.M. et al. | 2018
-
PHP213 - A RETROSPECTIVE REVIEW OF REIMBURSEMENT DECISIONS BY THE HAUTE AUTORITÉ DE SANTÉ IN 2017 - UNDERLYING RATIONALE FOR MEDICINAL PRODUCTS WITH INSUFFICIENT ACTUAL MEDICAL BENEFITMurphy, E.M. / Nwokoro, E. / Stanway, V.E. et al. | 2018
-
PHP197 - AN EVALUATION OF THE PERFORMANCE OF HOSPITAL PHARMACIES' GROUP PURCHASING ORGANIZATION TO PROMOTE HEALTHCARE MANAGEMENTPeikanpour, M. / Babapour, J. / Peiravian, F. et al. | 2018
-
PHP204 - VALIDATION OF A MULTICRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK TO INCORPORATE THE PATIENTS' PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENTGálvez, M. / Saldaña, R. / Palacios, M. / Badia, X. et al. | 2018
-
PHP184 - PATIENT INFLUENCE ON BIOSIMILAR UPTAKE: THE NOCEBO EFFECTPovsic, M. / Lavelle, P. / Enstone, A. / Rousseau, B. et al. | 2018
-
PHP171 - REVISITING REIMBURSED DRUGS WITH ALTERNATIVE PAYMENT MODEL IN TURKEY: 2016-2018Demir, O. / Senturk, A. / Kahveci, R. et al. | 2018
-
PHP152 - MECHANISMS OF ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLANDKapuśniak, A. / Caban, A. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP142 - SEVERITY ADJUSTED PROBABILITY OF BEING COST-EFFECTIVE: A NOVEL APPROACH TO INTEGRATE SEVERITY AND COST-EFFECTIVENESS WITH APPLICATIONS TO NORWAY AND THE NETHERLANDSVersteegh, M. / Corro Ramos, I. / Buyukkaramikli, N. / Ansaripour, A. / Reckers-Droog, V. / Brouwer, W. et al. | 2018
-
PHP100 - UTILIZATIONS AND EXPENDITURES OF TUMOR NECROSIS FACTOR ANTAGONISTS IN MEDICARE PART D: CROSS- SECTIONAL STUDY (2014-2015)Alghamdi, A. / Alduraibi, D. et al. | 2018
-
PHP57 - EUROPEAN CONDITIONAL MARKETING AUTHORIZATION – DOES EARLY MARKETING AUTHORIZATION TRANSLATE INTO EARLY REIMBURSEMENT AND PATIENT ACCESS?Macaulay, R. / Rothwell, S. / Sutcliffe, D. et al. | 2018
-
PHP66 - CURRENT OPPORTUNITIES AND CHALLENGES IN MARKET ACCESS OF E-HEALTH SOLUTIONSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
-
PHP34 - TIME ANALYSIS OF THE DRUG APPROVAL PROCESS IN EUROPEMartínez-Rodríguez, I. / Uría, E. / Pomares, E. / Cuesta, M. et al. | 2018
-
PHP40 - TRENDS IN THE INCLUSION OF NON-PHARMACEUTICAL HEALTH TECHNOLOGIES IN THE ISRAELI NATIONAL LIST OF HEALTH SERVICESTriki, N. / Samama, E. / Luxenburg, O. / Porath, A. / Ash, N. et al. | 2018
-
PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT: EXPERIENCES IN GERMANY 2018Oelze, I. / Neeser, K. / Mueller, E. et al. | 2018
-
PGI41 - CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN'S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNIONKarki, C. / Lu, Y. / Sharma, N. / Triggs, H. et al. | 2018
-
PHP2 - CHARACTERISTICS OF DOCTOR-SHOPPERS: A SYSTEMATIC LITERATURE REVIEWBiernikiewicz, M. / Taieb, V. / Toumi, M. et al. | 2018
-
PGI16 - THE ECONOMIC BURDEN OF CHRONIC INFLAMMATORY BOWEL DISEASE PATIENTS IN FINLANDTorvinen, S. / Ventola, H. / Herrala, S. / Schmidt, S. / Ylisaukko-oja, T. / Voutilainen, M. et al. | 2018
-
PGI19 - STANDARD-DOSE PROTON PUMP INHIBITOR IN THE INITIAL NON-ERADICATION TREATMENT OF DUODENAL ULCER: SYSTEMATIC REVIEW, NETWORK META-ANALYSIS, AND COST-EFFECTIVENESS ANALYSISZhang, J. / Xie, J. et al. | 2018
-
PGI9 - SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF INFLIXIMAB BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTSKaravitaki, M. / Kani, C. / Deutsch, M. / Markantonis, S. et al. | 2018
-
PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENTGomez-Ulloa, D. / Amonkar, M. / Kothari, S. / Cheung, W.Y. / Chau, I. / Zalcberg, J.R. / Nuria, L. / Falcone, A. et al. | 2018
-
PDB106 - ASSESSING THE HEALTH AND ECONOMIC IMPACT OF PHARMACEUTICAL CARE IN ELDERLY PATIENTS WITH DIABETES: A SYSTEMATIC LITERATURE REVIEWObeng, G.D. / Inotai, A. / Hankó, B. / Ágh, T. / Csanádi, M. et al. | 2018
-
PDB133 - CHRONIC KIDNEY DISEASE, HEALTH MEASURES AND HEALTHCARE UTILIZATION AMONG ADULTS WITH DISBETES IN THE UNITED STATESMeraya, A.M. et al. | 2018
-
PDB118 - SYSTEMATIC EDUCATION IN PATIENTS WITH T2DM SIGNIFICANTLY IMPROVES ADHERENCE TO THE TREATMENT. THE ADVICE STUDYDoupis, J. / Alexandrides, T. / Elisaf, M. / Melidonis, A. / Bousboulas, S. / Thanopoulou, A. / Pagkalos, E.M. / Pappas, A. / Arvaniti, E. / Karamousouli, E. et al. | 2018
-
PHP325 - ORPHAN DRUGS' MARKET ACCESS CHALLENGES IN EUROPE FROM A GERMAN PERSPECTIVEKirchmann, T. / Ewald, A. / Schönermark, M. et al. | 2018
-
PHP282 - NEW AIFA INNOVATION ALGORITHM: IS IT REALLY A STEP FORWARD IN ALIGNING AIFA'S DECISION WITH EUROPEAN HTAS?Digiacomo, F. / Capuano, C. / Walsh, K. / Yampolsky, D. et al. | 2018
-
PHP290 - IMPLICATIONS OF CONDITIONAL APPROVAL AND APPROVAL UNDER EXCEPTIONAL CIRCUMSTANCES BY THE EUROPEAN MEDICINES AGENCY ON NICE APPRAISALSNeez, E. / Naci, H. / Pinilla, P. / Osipenko, L. / Mossialos, E. et al. | 2018
-
PHP272 - QUANTITATIVE ASSESSMENT OF TECHNICAL ERRORS FOUND IN ECONOMIC MODELS SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Radeva, D. / Hopkin, G. / Naci, H. / Borrill, J. / Osipenko, L. / Mossialos, E. et al. | 2018
-
PHP267 - LANDSCAPE ASSESSMENT OF PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN EUROPEKönig, C. / Krinke, K. / Haas, J.S. / McLeod, K. / Braun, S. et al. | 2018
-
PHP230 - EU5 MARKET ACCESS FOR MEDICINES APPROVED UNDER EXCEPTIONAL CIRCUMSTANCESMycka, J. / Lobb, W. / Dellamano, R. / Dalal, N. / Dellamano, L. / Pereira, E. et al. | 2018
-
PHP229 - EU5 MARKET ACCESS FOR MEDICINES WITH CONDITIONAL MARKETING AUTHORISATIONSMycka, J. / Dellamano, R. / Lobb, W. / Dalal, N. / Dellamano, L. / Pereira, E. et al. | 2018
-
PHP221 - CONDITIONAL APPROVAL: ARE PAYERS REWARDING THESE HIGHLY NEEDED PHARMACEUTICALS?Auluck, J. / Conti, C.C. et al. | 2018
-
PDB97 - TYPE 2 DIABETES: OUTCOME OF DRUG TREATMENT IN PATIENTS INITIATING AGLP1 IN 2012: REAL-LIFE STUDY BASED ON SNIIRAM DATASemenzato, L. / Karsenty, D. / Aguade, A. / Fagot-Campagna, A. / Brun Buda, H. / Surroca, M. et al. | 2018
-
PDB87 - A COST-OF-CONTROL ANALYSIS: ONCE-WEEKLY SEMAGLUTIDE REDUCES COST OF REACHING TREATMENT TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN NORWAYHamidi, V. / Sverre, J.M. et al. | 2018
-
PDB88 - ADVENT OF MOBILE PLATFORMS LEVERAGES MULTISTAKEHOLDER COLLABORATION TO DRIVE OUTCOMES IN DIABETESEslami, N. / Marcarelli, A. / Zaidi, Q. / Garfield, S. et al. | 2018
-
PDB77 - LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTINGMontagnoli, R. / Lastoria, G. / Parekh, W. / Pöhlmann, J. / Hunt, B. et al. | 2018
-
PDB72 - PLATELET-RICH PLASMA IN DIABETIC FOOT ULCERS: COST-EFFECTIVENESS ANALYSIS FOR SPAINLinertová, R. / Del Pino Sedeño, T. / García-Pérez, L. / Aragón-Sánchez, J. / Kaiser-Girardot, S. / Trujillo-Martín, Md / Serrano-Aguilar, P. et al. | 2018
-
PCV144 - EFFECT OF CONVENIENCE OF ORAL ANTICOAGULANT THERAPY ON MEDICATION ADHERENCE: RESULTS OF AN INTERNATIONAL STATED PREFERENCE SURVEYVaanholt, M.C. / Weernink, M.G. / von Birgelen, C. / Groothuis-Oudshoorn, C.G. / IJzerman, M. / van Til, J.A. et al. | 2018
-
PDB5 - EFFECT OF STATINS USAGE ON INCIDENCE OF PERIPHERAL NEUROPATHY AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Zaitoun, M. / Mohamed Noor, D.A. et al. | 2018
-
PCV97 - HEARTH FAILURE IN VENETO REGION, ITALY: ANALYSIS OF THE THERAPEUTIC PATHWAYS AND CONSUMPTION OF HEALTH CARE RESOURCESDegli Esposti, L. / Perrone, V. / Sangiorgi, D. / Pitotti, C. / Ritrovato, D. / Menti, A.M. / Andretta, M. et al. | 2018
-
PCV70 - EFFECT OF TIME IN THERAPEUTIC RANGE ON COST AND CLINICAL OUTCOMES OF ATRIAL FIBRILATION PATIENTS : A COST-CONSEQUENCES ANALYSIS OF RIVAROXABAN VS WARFARIN FOR TURKEYKockaya, G. / Cavus, F. / Ozin, B. / Yilmaz, K.C. / Ciftci, O. / Oguzhan Ergın, G. / Sharaf, A. / Buyuktuna, N. / Buyukisik, T. / Saylan, M. et al. | 2018
-
PCN236 - IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTSDamen, D. / Templin, C. / Ulrich, S. / Kulp, W. et al. | 2018